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Introduction: Breast cancer patients with a depression diagnosis before or after cancer 
diagnosis have increased cost, shorter survival time and reduced adherence to hormone 
therapy.  Treating depression in these patients should improve these outcomes; however, 
there is scarce literature on this topic.  Currently, no study has determined the association 
of concurrent depression while adjusting for a history of depression or treating depression 
with antidepressants with cost, survival and adherence to hormone therapy.  This study 
has two objectives: 1) to determine the association of concurrent depression with cost, 
survival and adherence to hormone therapy adjusting for a history of depression 2) to 
determine the association of antidepressant use with cost, survival and adherence to 
hormone therapy in patients with depression. 
Methods: The SEER-Medicare dataset for 2005-2010 was used to address the study 
objectives.  Breast cancer patients with hormone receptor positive cancers diagnosed 
from 2006 to 2009 were identified from the SEER cancer registry.  Those who initiated 
hormone therapy within a year of cancer diagnosis were included in the initial population.  
A depression diagnosis was determined using ICD-9 codes.  Those who had an ICD-9 
code for depression within a year of cancer diagnosis were included in the final sample.  
Antidepressant use was determined from prescription drug claims and those who had at 
least one claim after a depression diagnosis were included in the final analysis.  
Generalized linear models (GLMs) were used to determine the association of 
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antidepressant use with adherence to hormone therapy and the incremental cost of 
antidepressant use among breast cancer patients with depression.  Kaplan-Meier curves 
were used to determine the initial association of antidepressant use with survival. 
Results: The final study population was 10,471 hormone receptor positive breast cancer 
patients who took hormone therapy within a year of breast cancer diagnosis.  Of these 
patients, 10% had a diagnosis of depression within a year of breast cancer diagnosis.  In 
breast cancer patients with depression, 62% took an antidepressant after their depression 
diagnosis.  Depression was associated with a statistically significant decrease in 
adherence (OR 0.81; 0.71-0.93) in the adjusted model.  Depression had a statistically 
significant 30% decrease in survival in the adjusted model.  Depression was associated 
with increased cost ($21,978.75) in the adjusted model; however, this was not statistically 
significant.  Adjusted general antidepressant use in breast cancer patients with depression 
had a non -significant reduction in the odds of adhering to hormone therapy (OR .79; .55-
1.14).  Those who took antidepressants for a year had a statistically significant increase in 
the likelihood of adhering to hormone therapy (OR 2.4; 1.61-3.65).  Adjusted general 
antidepressant use was not associated with survival in breast cancer patients with 
depression.  Continual antidepressant use for a year was associated with a statistically 
significant 60% increase in survival time in breast cancer patients with depression.  
Adjusted general antidepressant use was associated with a $27,840.50 increase in per 
patient per year cost; however, this difference is not statistically significant.  Continual 
antidepressant use for 90+ days was associated with a statistically non-significant 
decrease in per patient per year total medical cost. 
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Conclusion: Concurrent depression is associated with worse outcomes in breast cancer 
patients adjusting for having a history of depression.  Continual antidepressant use in 
breast cancer patients with depression is associated with improved adherence to hormone 
therapy and increased survival time.  The benefit of antidepressant use is time dependent 
and those who with longer use of antidepressants show more improvement compared to 
those who do not.  Antidepressant use increases per patient per year total medical cost; 
however, this is not a significant increase and continual use might be associated with 
decreased cost.  Extended antidepressant use in the depressed cancer population provides 
positive benefits to these patients by improving adherence to hormone therapy and 
survival and potentially reducing cost. 
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The aim of this chapter is to provide an overview of depression and antidepressant use in 
breast cancer patients.  A description of breast cancer and its importance will introduce the study 
population for the dissertation.  The key outcomes for this study are adherence to hormone 
therapy, survival and cost for breast cancer patients.  Discussion of each outcome begins with the 
association of depression followed by the association of antidepressant use for those who are 
depressed.  This chapter concludes with a statement about the gaps in the literature. 
1.2 Breast Cancer in the United States of America 
1.2.1 Introduction 
Breast cancer is a disease that affects both men and women in the United States and all 
parts of the globe.  It is also the most costly cancer in the United States1.  Simply, breast cancer is 
uncontrolled growth of cells in breast tissue that form a tumor2.  This disease is rare in men, but 
common in women.  Female breast cancer is one of the most common cancers in the United 
States.   If diagnosed at an early stage of tumor growth, female breast cancer has a good 
prognosis.  Varieties of treatments are available to improve survival in these patients.  There are 
still gaps in knowledge about the treatment of breast cancer patients despite the plethora of 




It is estimated that 12.3% of women will be diagnosed with breast cancer during their life 
with an estimated 231,840 women diagnosed in 2015 in the United States3.  The Surveillance 
Epidemiology and End Results (SEER) program reports that female breast cancer has an 89.4% 
five-year survival rate (2005-2011)3.  This survival rate leads to a higher prevalence of women 
with breast cancer in the United States, with an estimated 2,975,314 breast cancer cases in 20123.  
Prevalence has likely increased over time as the death rate reduced from 26 per 100,000 women 
in 2001 to 21.3 per 100,000 women in 20123.  Breast cancer affects women differently based off 
various demographic characteristics.  Women over 50, and Whites in the United States are most 
likely to develop breast cancer, while those who are Black have the highest mortality rate in 
breast cancer2. 
Breast cancer is the general term for cancer of the breast tissue2.  This general term 
indicates several types of cancers of the breast, which have distinctive characteristics.  These 
characteristics are the basis for distinct sub types, which have different treatments and survival 
probabilities.  These subtypes are the presence of the estrogen receptor (ER+), progesterone 
receptor (PR+) , human epidermal growth factor receptor 2 (HER2+), or the absence of all 3 
receptors (triple negative), or a mix of these combined2.  The most common of these subtypes are 
ER+ and PR+ tumors2, 4, 5.  The significance of ER+ and PR+ tumors is their need for estrogen 
and/or progesterone to grow6.  These cancers express receptors for estrogen and/or progesterone 
that allow them to use these hormones to promote growth.  Breast cancers with a majority of cells 
expressing one or both of these receptors are considered hormone receptor positive breast cancer 
or ER+/PR+6.  Those who are hormone receptor positive have a better 5-year survival outlook 




Surgery, chemotherapy and radiation are general treatments for all sub types of breast 
cancer2.  Surgery is defined as breast conserving surgery where minimal tissue is removed or a 
mastectomy where the entire breast is removed2.  The type of surgery depends on the 
characteristics of the patient and cancer.  Radiation is the use of high energy particles to kill 
cancer cells and generally follows breast conserving surgery and might follow a mastectomy 
depending on the characteristics of the cancer2.  Chemotherapy is the use of cytotoxic drugs to 
kill cancer cells and can be given before (neo-adjuvant) or after (adjuvant) surgery8.  
Chemotherapy is generally the most effective with a combination of drugs; however there is no 
combination that is more effective than others2. 
Targeted therapy is generally given if the breast cancer sub type is sensitive to targeted 
therapy.  The most common targeted therapy is hormone therapy to treat ER+ and PR+ breast 
cancers2.  Women who take hormone therapy for ER+ and PR+ cancers have an increased 
survival benefit9, 10.  Hormone therapy is given for at least 5 years as this time frame has been 
shown to provide the most survival benefit in these patients10.  Adherence to hormone therapy is 
an issue even with the benefit of increased survival11.   Approximately 62% of breast cancer 
patients who take hormone therapy adhere to the 5 year regimen12.  Improvement is needed for 
patients to complete 5 years of hormone therapy. 
1.2.4 Types of Hormone Therapy 
Hormone therapy contains two major categories, selective estrogen receptor moderators 
(SERMs) and aromatase inhibitors (AIs) 2, 13, 14.  Each category has the benefit of interfering with 
the growth of breast cancer, but they also have unique side effects.   
Tamoxifen is the most common drug in the SERM category14.  SERMs are estrogen 
receptor antagonist because they block the estrogen receptor in breast cells.  By blocking the 
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estrogen receptor, SERMs prevent tumors from using estrogen to promote growth6, 15.  Tamoxifen 
is the SERM of choice for treating ER+/PR+ breast cancer13, 15.  Tamoxifen has serious side 
effects which include blood clots, stroke, hot flashes, fatigue, mood swings and night sweats, 
which contribute to non-adherence to tamoxifen therapy14, 16. 
Anastrozole, letrozole, and exemestane are common drugs in the AI category.  AIs reduce 
estrogen in the body by blocking aromatase, a cytochrome P450 enzyme that creates estrogens 
from adrenal androgens and testosterone15, 17.   Anastrozole and letrozole are non-steroidal AIs 
that form a temporary bond with aromatase that keeps aromatase from making estrogens15.  
Exemestane is a steroidal AI that binds to aromatase and permanently inhibits aromatase from 
creating estrogens15.  Due to the clinical effectiveness of these AIs, they are now an alternative 
treatment to tamoxifen for postmenopausal and advanced cancers13, 17. AIs also have serious side 
effects, which include heart problems, osteoporosis, joint pain and hot flashes, which also 
contribute to non-adherence of AI therapy14, 16.   
1.2.5 Adherence to Treatment 
SERMs alone, AIs alone, or SERMs followed with AIs as therapy for at least 5 years 
show the best improvement in survival and reduction of recurrence6, 13, 18.  Adherence to hormone 
therapy is a concern due to drug side effects and the length of time to gain the benefit of 
survival19-22.  Menopausal symptoms and sides effects such as cognitive symptoms and 
musculoskeletal pain associated with hormonal therapy have been shown to be factors in reducing 
adherence to hormone therapy19, 20.  Studies observing adherence show a decrease in adherence 
over time for both SERMs and AIs12, 22-24.  Reduced adherence over time is a concern as women 
have poorer survival with reduced adherence12, 22, 23, or conversely, those who are adherent show 
improved survival9, 25-28.   
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Several studies have identified factors that predict non-adherence22, 23, 29-32.  Side effects 
were the most common reason for non-adherence found in these studies29, 30, 32.  Other reasons 
affecting adherence to hormone therapy include number of comorbidities, tumor size, using both 
a SERM and AI, and age.  One study did find that a decrease in the quality of life was a predictor 
of non-adherence29.  Adherence to hormone therapy is associated with several factors, which 
include patient characteristics, switching to an AI from a SERM and quality of life.     
Non-persistence or discontinuing therapy is a particular type of non-adherence that is also 
important in hormone therapy13, 33.  A person can be considered persistent but not adherent if they 
consistently take hormone therapy for 5 years but do not adhere to the recommended regimen 
during this time.  For example, a person may have been 10 days late to refill their hormone 
therapy but they do not stop taking it completely.  This person would be persistent but not 
adherent.  Studies have found that non-persistence is an issue for breast cancer patients taking 
hormone therapy12, 13, 33, 34.  These studies report that age, comorbidities and poverty level were 
associated with non-persistence.  A study by Hadji indicated a switch of therapy and depression 
were also associated with non-persistence33.                                   
1.2.6 Cost 
Breast cancer costs are categorized as direct or indirect cost.  Direct costs include all 
medical expenses incurred by breast cancer patients.  These costs can be breast cancer specific, 
all cost incurred by the patient or broken down to medical, pharmacy and other cost.  Indirect cost 
includes loss of productivity, time family spends caring for the patient, and life style changes due 
to breast cancer.   
Direct breast cancer cost was estimated to be $18.1 billion in 2014 in the United States1.  
Continuing care, including hormone therapy, cost $7.6 billion (42%) of the total cost for breast 
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cancer in 2014.  Within the first year of diagnosis, 39% of Medicare payments were direct cost of 
treatment in breast cancer patients in 2002.   
Breast cancer also has a high indirect cost.  Employers in the United States lost $12.1 
billion in 2005 due to breast cancer deaths for those over 201.  This estimate excludes other 
indirect cost such as lifestyle changes.  Lifestyle changes would include increased exercise, such 
as yoga classes, and cosmetic changes (wigs).  The patient incurs these extra costs, but they are 
not accounted for in medical cost or loss of work for an employer.   
Direct and indirect costs of female breast cancer make it the most costly cancer in the 
United States35  As indirect costs are hard to measure, studies have focused on direct cost, 
particularly the cost associated with hormone therapy.  Non-adherence to hormone therapy is a 
major contributor to the high cost of breast cancer36.  Those who were not adherent to hormone 
therapy had significantly higher medical cost during the 4 years of hormone therapy observed.  
There was no statistical difference in total cost (medical plus pharmacy) between those who were 
adherent and those who not adherent36.   
.  1.2.7 Summary 
Breast cancer affects many women in the United States and has several sub types that 
allow for specific treatments depending on the category.  The most common sub type is hormone 
receptor positive, which is treated with hormone therapy.  Adherence to hormone therapy is an 
issue due to the length of time of the therapy and side effects.  Breast cancer is also the most 
costly cancer in the United States with non-adherence to hormone therapy contributing to the high 
cost of breast cancer. 
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1.3 Depression and Breast Cancer   
 
Around 25% of breast cancer patients will be diagnosed with depression37-42.  The 
prevalence of depression in breast cancer ranges from 5% to 50% depending on the population 
studied and how depression was classified37-43.  Diagnosing depression is difficult as those taking 
chemotherapy have side effects that overlap with symptoms of depression42.  There is also 
evidence that those  taking hormone therapy will exhibit depressive symptoms as well44.  
Chemotherapy and rapid decline of estrogen due to hormone therapy is linked to cognitive 
impairment and depression40, 41, 45.  There is also evidence that breast cancer patients are prone to 
depression due to a change in cytokine levels from the cancer and chemotherapy45-49.   
The prevalence of depression in breast cancer is a concern due to its effect on adherence 
and survival.  Studies have established that depression has a negative effect on adherence in 
chronic diseases such as diabetes and hypertension50.  The association of depression with 
adherence to hormone therapy in breast cancer is not consistently reported in the literature.  A 
diagnosis of depression was associated with no effect or decreased odds of non-adherence to 
hormone therapy according to a review by Van Liew16.  Van Liew’s review indicated that having 
at least on comorbid condition was a predictor of better adherence.  Other views on the 
association of depression with adherence to hormone therapy are seen in other studies outside of 
Van Liew’s review20, 33, 51, 52.  These studies indicate a negative association of depression with 
adherence to hormone therapy.  Further, a meta-analysis of the literature showed depression is 
negatively associated with adherence to hormone therapy53.  Van Liew’s study is likely indicating 
that those who have a comorbid condition (i.e. depression), are more likely to be monitored by a 
physician and will be more adherent to hormone therapy as they are seeing a physician more 
often compared to if they did not have the comorbid condition.   
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Depression also has a negative impact on survival in breast cancer patients.  Goodwin 
found a 42% increase in the risk of 3 year mortality for those who were depressed in the SEER-
Medicare population54.  Studies that used different datasets report similar results55-57.  There is a 
biological mechanism for reduced survival in depressed cancer patients.  Studies show that breast 
cancer patients have increased levels of cortisol, a hormone that controls glucose intake by cells, 
which could lead to tumor cells exhibiting resistance to cortisol stimulation.  This resistance 
allows tumor cells to dominate glucose absorption and grow58.  Those who are depressed also 
exhibit increased levels of neuroendocrine hormones related to stress that promote tumor growth 
as well58, 59.  Breast cancer patients who exhibit depression after surgery have an impaired 
immune system response to breast cancer cells, indicating they are not able to fight off the cancer 
and potentially lead to a shorter survival time59.   
Cancer patients with depression have higher cost compared to those without depression.  
Breast cancer survivors who have depression show almost double the cost compared to those who 
do not have depression60.  
1.3.1 Summary 
Depression in breast cancer is a concern it negatively affects adherence to hormone 
therapy, survival and cost.  Those with depression have poor survival for two reasons.  The first is 
depression is associated with poor adherence to hormone therapy.  Adhering to hormone therapy 
improves survival and it has been shown that breast cancer patients who do not adhere to 
hormone therapy have worse survival compared to those who do adhere to hormone therapy.  
Depression also potentially weakens the body’s ability to fight breast cancer and lead to poor 
survival since the cancer will take over the body if allowed.  Those with depression also incur 
higher cost from increased healthcare utilization (direct medical and pharmacy) either by 
increased hospitalizations or increased physician visits and additional prescriptions. 
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1.4 Treatment of depression in breast cancer 
1.4.1 Overview 
Antidepressants and group therapy are two treatment modalities for depression in breast 
cancer patients61, 62.  Several studies show that group therapy is effective in treating depression 
symptoms in the breast cancer population62-66.  Antidepressants are also effective in treating 
depression in breast cancer patients67-70.   
Antidepressants have potential additional benefits in breast cancer beyond treating 
depression.  They have been shown to help alleviate menopausal symptoms, hot flashes, etc., in 
breast cancer patients on hormone therapy71.  This is probably due to their estrogenic effects72.  
Antidepressants also show anti-tumor effects in vitro73.   
Some antidepressants interact negatively with hormone therapy.  The most commonly 
prescribed antidepressant, selective serotonin reuptake inhibitor (SSRI), negatively interact with 
tamoxifen.  Tamoxifen is metabolized by cytochrome p450 2D6 (CYP2D6) into its active 
metabolites, which have a 100 fold increase in the ability to block the estrogen receptor74.  SSRIs 
inhibit CYP2D6, which reduces the active metabolites of tamoxifen in breast cancer patients on 
tamoxifen therapy74.  Studies have addressed the potential negative interaction of SSRIs with 
tamoxifen.  Three studies found no effect of SSRIs on tamoxifen’s protective effect against 
recurrence75-77.  One study  reported the SSRI paroxetine did block tamoxifen’s protective effect 
on survival78.  Following these studies, an editorial by Breibart indicated that certain SSRIs, like 
paroxetine, should not be given concurrently with tamoxifen as they are considered strong 
inhibitors of CYP2D6.  SSRIs considered milder inhibitors of CYP2D6 could be given 
concurrently with tamoxifen79.  This concern is reflected in a transition from use of SSRIs 
regarded as strong inhibitors to those that are weak inhibitors of CYP2D6 in tamoxifen users over 
time80. 
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1.4.2 Depression treatment and cancer outcomes 
As stated previously, depression is associated with worse outcomes; therefore, treating 
depression should be associated with improved outcomes.  In the scare literature determining an 
association of depression treatment with outcomes, treating depression potentially improves 
outcomes in those with depression.  Breast cancer patients with depression who were treated with 
the antidepressant fluoxetine showed improved completion of both chemotherapy and hormone 
therapy81.  Depressed metastatic breast cancer patients who had reduced depression scores had 
improved survival82.  Treating depression in breast cancer has mixed results on cost.  One study 
finds no difference between the treated (group therapy) and untreated groups for both cost and 
utilization83.  A literature review indicated that psychosocial interventions are inexpensive and do 
not significantly increase cost in the treated group and found that this intervention was cost 
effective as it increased quality adjusted life years84.  A Canadian study in cancer patients 
reported a 23% reduction in total cost in breast cancer patients with depression who received 
group therapy85.  In diabetes, a chronic condition like cancer, treating depression systematically 
showed increased total cost in the first year but reduced total cost by the second year86.  Another 
study found short term cost for treating depression with group therapy is significantly higher 
while those on antidepressants are not significantly higher87.  At this time, it is unknown how 
treating depression with antidepressants over the course of hormone therapy will influence cost.        
Treating depression with group therapy or antidepressants potentially improves 
adherence to hormone therapy and survival in breast cancer.  Breast cancer patients with 
depression do have higher cost if they are treated with antidepressants or group therapy; however, 





Breast cancer is a costly disease that affects a large proportion of women.  Breast cancer 
has several sub types that are characterized by distinct clinical markers.  The most common sub 
type is hormone receptor positive where the cancer cells express the estrogen and/or the 
progesterone receptor.  These cancers are able to use hormones to promote their growth so the 
traditional therapy is to block these receptors either directly using SERMs or at the source using 
AIs.  Due to side effects and length of hormone therapy, adherence and persistence to hormone 
therapy are clinically important issues.  There is no consensus on how depression affects 
adherence and persistence in breast cancer; however, it is likely that there is a negative 
association of depression with adherence to hormone therapy.  Cost and survival are both 
negatively affected by depression.  Treating depression potentially improves adherence and 
survival and initially raises cost; however, cost might be reduced over time.   
There are gaps in the knowledge of how depression and antidepressant use impact 
adherence to hormone therapy, cost and survival in breast cancer patients.  The association of 
depression with adherence to hormone therapy, survival and cost adjusting for a history of 
depression is not known.  The association of antidepressant use with adherence to hormone 
therapy, survival and cost in the majorly depressed population is not known.
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
 
This chapter will present the current literature that describes the effect of depression and 
depression treatment on adherence to hormone therapy, survival and cost in breast cancer 
patients.  This chapter will begin with a description of adherence, survival and cost followed by a 
detailed analysis of the relevant studies.  Each analysis will include the purpose of the study, 
source of the data, study population, how relevant variables were operationalized, sample size, 
analysis used, relevant results, discussion of results and overall conclusion from the study.  For 
each subsection, non- significant results are presented first followed by significant results.  Each 
subsection will conclude with a summary of the presented studies followed by the identification 
of the gap in the literature.  Each major section will conclude with a summary of all presented 
literature and the gaps found in the presented literature.  This chapter will conclude with the aims 
and hypotheses of this study. 
2.2 Definitions of Outcome Variables  
 
2.2.1 Adherence 
Medication adherence is the extent to which a patient follows their treatment regimen 
over a period of time51.  Non-persistence or discontinuation is defined by an extended period of 
time between prescription drug fills, for the same drug, and indicates a patient stopped taking 
their therapy33.  The length of time that defines when a person is non-persistent ranges from 90 to 
over 180 days between prescriptions in breast cancer patients33, 52.  A patient who is not persistent 
is also considered non- adherent.  Pill count, electronic monitoring, self- report, medication 
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possession ratio and percent days covered are ways to measure adherence in breast cancer 
patients taking hormone therapy20, 22, 51, 88.    
2.2.2 Survival 
Survival in cancer has two components, namely length of time from diagnosis to death, 
and cause of death, specifically cancer-specific or other cause54, 55, 57, 89.   
2.2.3 Cost 
Cost can be calculated several ways in the health care setting depending on the 
perspective.  From a societal perspective, cost would include all direct medical cost in addition to 
other indirect cost.  Examples of indirect cost are absence and loss of productivity to a company 
due to illness and transportation to and from a health care facility.  From the patient perspective, 
cost would include direct medical out-of-pocket cost in addition to the transportation and loss of 
salary due to illness.  In the literature, the focus is generally on direct medical cost. 
 
2.3 Association of Depression with Hormone Therapy Adherence, Survival and Cost 
in Breast Cancer  
 
2.3.1 Association of depression and adherence to hormone therapy  
Table 2.1 summarizes several studies that examined the association between adherence to 
hormone therapy and depression.  There is lack of consistency in the conclusions about the 
association of depression with adherence to hormone therapy.  Studies ranged from a significant 
improvement in adherence to hormone therapy to a significant reduction in adherence to hormone 
therapy for those who are depressed.   
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Four studies found improvement (significant and non-significant) in adherence to 
hormone therapy for those who were depressed33, 51, 90, 91.  All four studies were in European 
populations and two used the same dataset.  Only two of these studies were designed to determine 
an association of depression with adherence33, 90.  The study by Huiart is unique in the breast 
cancer literature as it focuses on a younger population (<40 years of age)90.  This study is not 
generalizable to the general breast cancer population because most breast cancer patents are older 
(>60), and there are differences in how those who are 40 are affected by breast cancer compared 
to those who are over 60.  Huiart's study also has a smaller sample of 246, with only 49 being 
depressed, which also limits generalizability.  It is likely that these results (RR=.8 for non-
persistence) would be significant with a larger sample size.  Hadji's study is in the elderly 
population, but focuses on the type of care a patient received in Germany33.  This study is in the 
elderly population and is generalizable to these patients.  Of note, the hazard ratio of .92 for 
depression is closer to one compared to Huiart's study, but with a sample of 12,412; a significant 
result is expected.  A distinct difference between these two studies is Huiart identified depression 
at 10 months after breast cancer diagnosis compared to Hadji who identified depression before 
breast cancer diagnosis.  A potential explanation for consistently observing an indication of a 
positive association of adherence to hormone therapy with depression is those who are depressed 
are more likely to see a physician more often, which would lead to them to be more adherent to 
hormone therapy because they are seeing a physician more regularly compared to those who are 
not depressed.  Of interest, Ziller's study indicated a differential effect of baseline depression on 
hormone therapy adherence between those on tamoxifen vs AIs51.  The design of this study was to 
characterize these patients in a non-experiment setting, not determine predictors of non-
adherence.  Those on tamoxifen with baseline depression showed improved adherence to therapy 
(non-significant OR=1.22) compared to those on AIs with baseline depression who showed 
reduced adherence to therapy (non-significant OR=.96).  With samples larger than 65 and 72 for 
tamoxifen and AI users, respectively, these results would likely become significant.  Like Hadji’s 
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work, this study was in the elderly population and potentially generalized to the general breast 
cancer population.       
A negative association of depression with adherence to hormone therapy was indicated in 
five other studies20, 29, 52, 88, 92.  Of these studies, three showed a non-significant association of 
depression to adherence to hormone therapy29, 52, 92.  The study by Grunfeld indicated that those 
who were not adherent to hormone therapy had a non-significant increase in depressed mood 
compared to those who were adherent, based on a sample with only 13 who were not adherent92.    
Like Ziller’s work, this study aimed to characterize patients who were non- adherent to hormone 
therapy.  The other two studies that showed a non-significant decrease in adherence to hormone 
therapy for those who were depressed did focus on predictors of adherence to hormone therapy29, 
52.  These studies did not directly measure depression and relied on self-report or medication use 
to distinguish patients who had depression.  Concurrent depression was associated with increased 
risk of discontinuing therapy in both studies (non-significant).  Kemp showed a significant 
increase in the risk of discontinuing therapy for those who were concurrent/newly depressed 
(HR=1.19) before adjusting for covariates such as tumor size and clinical stage.  When adjusted 
for all covariates, this increased risk was not significant.  Kemp also examined a history of 
depression and found a non –significant increase risk of discontinuing therapy52.     
Two studies were designed to determine the association of depression with adherence to 
hormone therapy, and they both found a significant negative association of depression with 
adherence20, 88.  Both of these studies used a depression scale to determine depression status and 
used an alternative to pharmacy claims to determine adherence.  Data were collected via 
electronic monitoring of pill caps and in person interviews in Bender's study.  A strength of 
Bender's study is the use of random coefficients modeling, which allows the use of repeated 
measures for adherence over time.  As adherence changes over time, this model allows for this 
variation in determining predictors of non-adherence.   The parameter for univariate analysis 
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predicting adherence for the Beck depression score (a higher score indicates more severe 
symptoms) was     -.8845 (p<.01) at baseline and -.3106 (p>.05) as a time dependent variable.  
This indicates that a higher Beck score at baseline is associated with reduced adherence (p<.05) 
and indicates a negative association over time (p>.05).  This study’s sample of 91 limits the 
power to detect statistically significant differences and a larger sample might have shown a 
statistically significant decrease in adherence for those who developed depression during the 
study.  A limitation for this study is that the analysis did not account for the other variables in the 
study, which would alter the effect of the Beck score on adherence.  Of note, adherence was a 
continuous variable and the analysis was for a 1% increase in days of therapy taken.  This 
consideration indicates that the estimates are likely conservative estimates and those with more 
depressed symptoms have a significantly reduced likelihood of adhering to hormone therapy. 
Klepin's study of cognitive factors associated with adherence to tamoxifen and raloxifen 
(Co-STAR) used 6 month follow-up information taken in-person and a baseline standardized 
neuropsychological test that consisted of several cognitive tests that covered different areas of 
cognition88.  These areas include memory, verbal fluency and global function.  This is a nested 
study from a randomized clinical trial examining differences in tamoxifen and raloxifen.  
Adherence was measured every 6 months by pill count when a patient came into the clinic for the 
randomized trial and was condensed to a single measure for the entire period in this follow up 
study.  Multivariate logistic regression showed that a higher baseline depressive symptom score 
was associated with a significant 13% increase in the odds of non-adherence.  This result 
indicates that more depressive symptoms at baseline are significantly associated with non-
adherence to hormone therapy.  Of note, this study was not in the breast cancer population, but 
those who were at risk for breast cancer.  One limitation is the use of a condensed adherence 
variable instead of repeated measures.  A more appropriate analysis would be the use of the 6-
month measures in a repeated measures analysis instead of a single measure for up to 5 years. 
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There appears to be a negative association between depression and adherence.  The 
studies that indicated a positive impact of depression on adherence do not provide support for this 
association in the general breast cancer population.  The use of a young population or small 
sample size indicates limited external validity for Huiart and Ziller51, 90.  The only claims analysis 
done that indicated a positive association assessed discontinuation and not adherence33, 91.  In the 
claims analysis they did not account for a potential increase in utilization of physician visits due 
to depression as a potential reason for the positive association observed.  As these analyses 
included the type of physician practice a person visited, the negative effect of depression might 
have been observed in the poorer physician practice and the depression variable itself indicates 
the association of more physician visits with increased persistence.  These studies do not support 
a strong positive association of depression with adherence to hormone therapy.  Of the five 
studies indicating a negative association of depression and adherence to hormone therapy, three 
used prospectively collected data from a clinical trial or other project20, 52, 88.  Only two of these 
studies directly obtained information on depressive symptoms20, 88 and only one used a large 
sample size88.  Only Bender, used a repeated measures analysis for adherence over time.  As 
adherence to hormone therapy drops over time, using repeated measures allows for a more 
detailed analysis of predictors of non-adherence22.  No study reports the association between 
depression and adherence to hormone therapy using a large database with a repeated measures 
design.  
2.3.2 Depression and survival 
Table 2.2 summarizes four studies that examined the association between survival and 
depression.  All studies found a significant reduction in survival for those with depression.  These 
studies focus on a prior diagnosis of depression and not concurrent depression.  Each study 
provides a different perspective on the association between depression and survival in breast 
cancer patients.   
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Onitilo's study used a general approach that observed four groups of people from the NHANES 
population55.  These groups were those with no cancer without depression, no cancer with 
depression, cancer with no depression; and cancer with depression.  Mortality was determined 
either with the National Death Index or by a proxy interview that determined a patient’s vital 
status.  The authors reported hazard ratios of 1.42, 1.24 and 1.7 (p<.05 for all) for those with 
cancer without depression, no cancer with depression and cancer with depression, respectively 
compared to those with no cancer without depression adjusting for various demographic 
characteristics.  The authors reported a breast cancer specific hazard ratio of 1.27 (p>.05) that 
adjusted for various demographic characteristics.  The sample size of 136 for all breast cancer 
only patients is likely too small to detect significant differences between those with depression 
and those without depression.  A limitation of this study is the inability to adjust for cancer 
specific confounders, which would influence survival, such as stage of cancer that is an indication 
of cancer severity.  Another limitation of this study is the inability to determine if depression was 
diagnosed before or after breast cancer diagnosis.        
Hjerl’s more focused design found mixed results for the direct association of depression 
with survival in early  and late stage breast cancer patients 89.  In the 10,382 women with early 
stage breast cancer those with depression before or after cancer diagnosis had relative risks of 
1.23 (p>.05) and 1.73 (p<.05), respectively for death due to all causes.  Relative risks for the 
10,211 late stage breast cancer patients were 1.34 (p<.05) and .96 (p>.05) for those with 
depression before or after breast cancer diagnosis respectively.  All risks were adjusted for 
clinical characteristics that would affect survival and those with late stage cancers were 
additionally adjusted for tumor size and the number of positive lymph nodes.  This study 
indicated that depression increases the risk of death due to all causes in early stage breast cancer 
while only preoperative depression significantly increases the risk of death due to all causes in 
late stage cancer patients.  This is the first study to indicate that the timing of depression may 
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have a differential effect on survival depending on the stage of cancer.  The strength of this study 
is the large sample size and additional adjustments for confounders.  Another strength is the 
generalizability to a broader breast cancer population; however, this study used data from 1978-
1993 from Denmark.  An updated study is needed to determine if these results are applicable to 
the current population.   
Vodermaier focused on 1,646 early stage breast cancer patients from two cancer centers 
who did or did not have a prior diagnosis of depression57.  Those with a prior diagnosis of 
depression had a 154% (p=.02) increased risk of death due to all- causes adjusting for clinical and 
demographic characteristics.  A strength of this study is the comprehensive adjustment for 
confounders and a large enough sample size to generalize to a broader breast cancer population.   
Goodwin’s SEER-Medicare study is the only United States claims based study to 
examine the impact of depression on survival in breast cancer54.  The purpose of this study was to 
determine if a prior diagnosis of depression had an effect on 3-year survival in breast cancer 
patients.  The final population of 24,696 breast cancer patients was analyzed.  A prior diagnosis 
of depression had a 142% increase in the risk death within 3 years of diagnosis (p<.05) adjusting 
for some con founders.  A limitation of this study was that tumor type (ER/PR + etc.), initial 
surgery, radiation use, chemotherapy use, tumor size and grade were not included in the analysis.  
These are all important factors that affect survival in breast cancer.  Of note, this study used data 
from 1993-1996 and an updated analysis is need to determine the impact of prior depression on 
the current United States breast cancer population.  An important strength is the use of SEER-
Medicare, which is a representative database for all Medicare breast cancer patients in the United 
States.  A study is needed to determine the effect of prior depression on survival adjusting for all 
confounders in the current SEER-Medicare population.    
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The literature shows a prior diagnosis of depression is associated with a significantly 
increased risk of death in breast cancer patients.  Only one study accounted for the effect of 
concurrent depression on survival, and was in a Denmark population from 1978-1993.  The only 
United States claims study looked at a prior diagnosis of depression and did not fully adjust for 
all confounders.  There is no claims based analysis in the United States to determine the impact of 
concurrent depression on survival that also adjusts for a history of depression and all confounders 
in breast cancer.  
2.3.3 Depression and cost 
Table 2.3 summarizes the studies that examine the association between cost and 
depression.  Only two studies determined the incremental cost of depression in cancer, and 
neither specifically looked at breast cancer.  Other studies did not determine the incremental cost 
of depression, only the cost in patients with depression compared to those without depression.  
Only one study specifically examined cost in women with breast cancer and depression.    
The study that specifically assessed cost in depressed breast cancer patients reported that 
those with depression incurred $15,471 annually compared to $8,297 in breast cancer patients 
without depression60, 93.  Jeffery used the Military Data Repository (MDR) for this study and 
calculated costs as the total cost the Department of Defense paid to providers during fiscal year 
2009.  The final sample included 11,014 cancer patients, 2,851 (26%) breast cancer, for analysis.  
Incremental cost of depression in cancer patients was not calculated, and each cancer was 
analyzed separately, but the results were not reported in the primary article.  A news article on 
this paper reported breast cancer specific results60.  A limitation of this study is the use of a 
military database, which is not generalizable to the general breast cancer population.  This is the 
only study to show that depressed breast cancer patients incur higher cost compared to non-
depressed breast cancer patients.  
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Only one study determined the incremental cost of depression in cancer, which includes 
breast cancer.  Pan determined the incremental cost of depression in all cancer patients in the 
Medical Expenditure Panel Survey (MEPS) population94.   Cost was calculated as total health 
expenditures, which include all insurance payments, and out of pocket payments by the patient 
and reported in 2009 dollars.  Ordinary least squares (OLS) of log transformed cost and 
generalized linear models (GLM) with a log link and Gaussian distribution were used to 
determine the incremental effect of depression on cost.    OLS showed a 32% increase in total 
cost, 16% increase in outpatient and 107% increase in prescription cost for those who were 
depressed adjusting for demographic and clinical confounders (p<.001 for all).  GLM showed that 
those with depression incurred an extra $2,213 total cost (p<.05) and $913 (p<.01) prescription 
cost compared to those without depression adjusting for clinical and demographic confounders.  
GLM also showed that those who are depressed had a reduction of $329 for outpatient cost.  One 
limitation of this study is the inability to account for cancer specific factors such as stage that will 
influence cost as those with more severe cancers will have higher cost compared to those with 
less severe cancers.  A strength of this study is the generalizability to all United States cancer 
populations as MEPS is nationally representative.  Another strength is the use of a GLM with a 
log link and a Gaussian distribution to account for the skewed nature of cost.   
Jayadevappa used SEER-Medicare to the effect of depression on cost in men with 
prostate cancer95.  Cost was calculated as direct medical cost Medicare paid in reimbursements 
and reported in 2009 dollars using a 5% discount rate.  A generalized linear model with a log-link 
and gamma distribution reported the effect of depression on cost.  Depression diagnosed during 
treatment showed significantly increased cost (1.52 odds to 1.34 odds) for the years 1 to 4 after 
cancer diagnosis and 1.43 odds the last year before death.  Depression diagnosed after treatment 
showed significantly increased cost (1.51 odds to 1.89 odds) for years 2-5 and 1.26 odds the last 
year before death.  A limitation of this study is the authors only report the odds and not the actual 
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cost even after they explain that is the advantage of using GLM.  The authors did not take 
advantage of this tool to report the incremental cost of depression in prostate cancer.  Another 
limitation is that they did not adjust for cancer specific variables such as stage, tumor size, or 
surgery type.   
The literature shows that depression increases direct medical cost in cancer.  Only one 
study showed the incremental cost of depression in cancer, and it was unable to account for 
cancer specific confounders.  Two studies use a GLM to examine cost, which is an appropriate 
analysis to account for the skewed nature of cost.  There is one study to compare the cost incurred 
by depressed breast cancer patients to non-depressed breast cancer patients; however, the study 
did not determine the incremental cost of depression and was in a select breast cancer population 
that did not reflect the general breast cancer population.  No study in the literature determined the 
incremental cost of depression in breast cancer using generalized linear models. 
2.3.4 Summary of Depression in Breast Cancer 
The literature for depression and breast cancer shows that depression has negative effects 
on adherence to hormone therapy, survival and cost.  The literature that examined the association 
between depression and adherence contains differing results.  The studies that indicated a positive 
association between depression and adherence have two limitations:  1) a unique population not 
indicative of the general breast cancer population and 2) potentially increased monitoring due to 
more doctors’ visits because of a depression diagnosis.  Studies that showed a negative 
association of depression with adherence were in a prospective setting and generally used a single 
adherence measure.  There has not been a retrospective claims study using repeated adherence 
measures to examine the effect of depression on adherence to hormone therapy.  Studies 
examining the association of depression with survival all found a significant decrease in survival 
for those who were depressed.  These studies focused on a prior diagnosis of depression and not 
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depression during breast cancer.  The one generalizable United States study did not account for 
several confounders in their analysis.  No study has examined the impact of depression during 
breast cancer on survival that accounts for all available confounders in the United States.  Cancer 
patients with depression have increased cost and the only study that specifically observed breast 
cancer patients did not determine the incremental cost of depression and was in a unique 
population.  Other studies that determined incremental cost of depression in cancer patients used 
a GLM, a model that is able to account for the skewed nature of cost without transforming cost 
before the analysis.  The incremental cost of depression in breast cancer patients has not been 
determined using a GLM.    
2.4 Breast Cancer and Treatment of Depression 
 
2.4.1 Adherence and depression treatment 
Table 2.4 summarizes three studies that examine the association between adherence to 
hormone therapy and antidepressant use.  These studies show mixed results on this association 
that range from significant improvement to a significant reduction in adherence to hormone 
therapy; however, none of these studies focused on those who had a diagnosis of depression. 
Two studies indicated a reduction in adherence to hormone therapy for those taking 
antidepressants19, 24.  Trabulsi reported that antidepressants negatively affect adherence to 
hormone therapy in 4,715 elderly breast cancer patients24.  Antidepressants at baseline reduced 
adherence by 4.7% (p=.004) adjusting for various clinical and demographic characteristics.  A 
limitation is that depression was not controlled for in the analysis, which potentially indicates that 
antidepressants are a proxy for depression.  Therefore, these results do not show the association 
of antidepressant use with adherence to hormone therapy in the depressed population.  Another 
limitation of this study is the use of a single measure of adherence for 5 years instead of repeated 
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measures.  Using a repeated measures analysis would allow patients to be followed over time.  
The study by Cluze did observe depressive symptoms and still found a reduction in adherence for 
those on antidepressants19.  In the univariate analysis, antidepressants had a 1.91(p>0.2) increase 
in the odds of early non-persistence while those with a CES-D score >23 (French cutoff for 
depression96) had a 0.76 (p>0.2) decrease in the odds of early non-persistence.  Antidepressants 
also had a 1.36 (p>.2) increase in the odds of late non-persistence and depression had a 
2.48(p>.2) increase in the odds of late non-persistence.  The p-value in the univariate analysis did 
not meet the required <.2 cutoff to be included in the multivariate analysis for antidepressant use 
and depression.  As these odds ratios are not adjusted, antidepressant use is likely a proxy for 
those with major depression as indicated above.  As depression was not accounted for in the 
analysis in both papers, antidepressants might decrease the risk of non-persistence in breast 
cancer patients with depression.              
Navari’s study  is the only one that examined the effect of antidepressants on completion 
(adherence) to hormone therapy in 193 breast cancer patients with depressive symptoms81.  The 
fluoxetine (antidepressant) group had a significantly higher rate of completing adjuvant therapy 
(87%) compared to placebo (50%) (p<.01).  A limitation of this study is the short observation 
period, particularly for hormone therapy.  As patients take hormone therapy for at least 5 years, 
the concern of non-adherence is after the first year or two.  This study was also not in clinically 
depressed patients, but it is likely that those who are clinically depressed would benefit more 
from treatment than those who are not.  Another limitation is it is not generalizable past early 
stage breast cancer patients with mild depressive symptoms.  The strength of this study is its 
internal validity that comes with a double blind randomized controlled trial.  This study indicates 
potential causality between fluoxetine treatment and completing adjuvant treatment at 6 months.     
The literature is conflicted on the impact of antidepressants on adherence to hormone 
therapy; however, only one study observed those with any depressive symptoms.  The two studies 
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that indicate a negative effect of antidepressants on adherence to hormone therapy do not account 
for a diagnosis of depression.  In these studies, antidepressant use is likely a proxy for depression, 
which has been shown to negatively effects adherence to hormone therapy.  The one study that 
established that antidepressants improve adherence was in a small sample and in the non-
clinically depressed population.  As an association was established in Navari’s study, a large 
study in the clinically depressed population will determine if these results are generalizable to the 
larger breast cancer population.  No claims-based study to determine the impact of antidepressant 
use on adherence to hormone therapy has been done in the clinically depressed breast cancer 
population.    
2.4.2 Survival and depression treatment 
Table 2.5 summarizes five studies that examine the association between survival and 
depression treatment.  Three studies examined antidepressant use for depression treatment and 
two studies examined group therapy for depression treatment. 
The two studies that examined group therapy were both randomized controlled trials and 
were not in a clinically depressed population64, 82.  The study by Goodwin did not show any 
improvement in survival for those in group therapy (median 17.9 months survived) compared to 
control (median 17.6 months survived)64.     Giese-Davis showed a significant increase in survival 
time for those who had lower depressive scores (median 53.6 months) compared to those did not 
(25.1 months)82.  Of note, Giese-Davis did not determine if group therapy was effective in 
reducing depressive symptoms compared to the control group.  These studies indicate that in the 
non-depressed population, survival is improved by decreasing depressive symptoms not with 
group therapy. 
Of the three studies that examined the association of antidepressant use on survival, only 
one was in a group that exhibited depressive symptoms and none were in a clinically depressed 
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population28, 70, 78.  In the two studies with no depressive symptoms, a mixture of results were 
reported.  Weaver reported that those who use CYP2D6 inhibitors (half of which were 
antidepressants) reduced the risk of death by 17% (p>.05) adjusting for adherence and clinical 
and demographic characteristics28.  There are two considerations when examining these results.  
The first is this was not in the depressed population and the reduction could be significant in the 
depressed population.  The second is the effect could be due to the inhibitors that were not 
antidepressants examined in this study instead of the antidepressants.  Also, there could be 
differential effects of specific antidepressants, which are not captured in this study.  The study by 
Kelly indicates that there are differential effects of antidepressants on survival for breast cancer 
patients on tamoxifen78.  The adjusted cox proportional hazards model indicated a potential 
positive association for the antidepressant fluoxetine and survival, reduced risk of death due to all 
causes by 5% (p>.05).  The adjusted model indicated a negative association of other 
antidepressants with survival; most associations were not statistically significant.  Paroxetine had 
a statistically significant 146% increase in the risk of death due to all causes.  There are two 
important factors to consider in interpreting these results.  The first is this may not be in the 
depressed population.  Antidepressant use could be a proxy for depression, which is one reason 
why there is a potential negative association indicated in this study.  If antidepressants are a proxy 
for depression, then there is no other variable in this study that would indicate depression is being 
treated by an antidepressant.  This study would then be reporting the association of depression 
and not antidepressant use.  Also, antidepressants could also be prescribed for other reasons that 
are not related to depression, such as treating menopausal symptoms71.  In the depressed 
population, it is possible that antidepressant use improves survival.  The second is this was in a 
tamoxifen only population and the only antidepressants examined were SSRIs.  In tamoxifen 
users, there is a debate in the literature about the potential negative effects of SSRIs on tamoxifen 
metabolism and benefits74, 76, 97, 98.  Published literature indicates that SSRIs fluoxetine and 
paroxetine potentially reduce the effectiveness of tamoxifen, but other SSRIs and other classes of 
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antidepressants do not reduce tamoxifen’s effectiveness98.  Of note, there has been no debate 
about SSRIs for those who use aromatase inhibitors.   
Only one study examined the impact of antidepressant use on survival in cancer patients 
exhibiting depressive symptoms.  Fisch reported a non-significant decrease in median survival 
time for those who took fluoxetine (6 months) compared to placebo (9 months) in a clinical trial 
by the Hoosier Oncology Group70.  The strength of this study is the internal validity to determine 
causality for the effect of fluoxetine on survival.  The randomized clinical trial design balances 
both observed and non-observed confounders between groups and the only difference between 
these groups is the taken drug.  If there is only one difference between these groups, that 
difference is the cause for the reported results.  One limitation is these patients were not clinically 
depressed, so there could be a positive effect of fluoxetine on survival.  Of interest, the survival 
curves do cross in the second year of follow up with those on fluoxetine exhibiting a longer 
survival time compared to those on placebo.  This indicates that a positive effect of antidepressant 
use is seen over time rather than immediately in depressed cancer patients.   
The literature shows that a decrease in depressive symptoms is indicative of better 
survival.  Antidepressants do improve depressive symptoms; however, the use of certain SSRIs in 
treating depression in tamoxifen users may not improve survival due to negative drug 
interactions.  Only one study examined antidepressant use in those with depressive symptoms and 
indicated that any positive effect would be seen over time and not immediately in cancer patients.  






2.4.3 The impact of depression treatment on direct medical cost 
Table 2.6 summarizes the three studies that examine the association between direct 
medical cost and depression treatment.  All studies observed group therapy as a treatment for 
depression.   
Two studies looked at group therapy only and found no significant increase in cost for 
this intervention83, 99.  Simpson’s study indicated that the intervention significantly reduces cost 
for those who have high medical expenses; however, this was not in the depressed breast cancer 
population99 .  Lemieux’s study indicated a non-significant reduction in cost for those who are 
distressed at baseline and took part in group therapy83.  These studies were both in the Canadian 
breast cancer population and were not in the depressed population. 
A U.K. study by Strong examined the cost of group therapy and indicated cost of 
antidepressant use as part of this intervention for depressed cancer patients100.  The average total 
cost of the intervention was £334.86 ($670) per 6 months, which included antidepressant cost.  
Antidepressant costs were £70.11(~$140) vs £20.79(~$42) for those in group therapy or not, 
respectively.  The difference is likely due to those in group therapy being more diligent in taking 
antidepressants compared to those who are not in group therapy.  This is the only study to 
indicate cost of antidepressant use in depressed breast cancer patients.  The results indicate that 
antidepressant users would not have significantly increased costs in the depressed population.  A 
direct estimate of antidepressant cost in the United States cannot be made from this paper due to 
differing pricing policies in the U.K. versus the United States.            
The literature for cancer and depression treatment is sparse and focuses on group therapy.  
There is an indication that antidepressant use would not significantly increase cost, and 
potentially reduce direct medical cost in the depressed population.  There is no study in the 
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United States that has determined the effect of antidepressant use on direct medical cost in the 
depressed breast cancer population.   
2.4.4 Summary of Antidepressant use in the Depressed Breast Cancer Population 
The literature examining the impact of treating depression (group therapy or 
antidepressant) on adherence, survival and cost is sparse and focuses on those with depressive 
symptoms instead of those with a diagnosis of depression.  Studies examining the impact of 
antidepressants on adherence do not account for a depression diagnosis or are in those with mild 
depressive symptoms.  These studies indicate that antidepressants potentially increase adherence 
to hormone therapy in depressed breast cancer patients.  Studies show that antidepressant use has 
mixed results with survival in breast cancer; however, they were not in the depressed population 
and only focused on one class of antidepressants.  Treating depression improves survival, but no 
study has looked at all antidepressants and their effect in the depressed population.  
Antidepressant users would likely incur a non-significant increase in direct medical cost 
compared to non- users; however, the study was in a U.K. population, who have differing pricing 
policies compared to those in the United States.  No study has determined the effect of 
antidepressant use on direct medical cost in the depressed breast cancer population. 
2.5 Overall Summary 
 
Depression negatively affects hormone therapy adherence, survival and cost in breast 
cancer patients.  The studies that indicate a positive association of depression with adherence to 
hormone therapy are in a unique population and do not take into consideration increased 
monitoring by physicians due to a diagnosis of depression.  Studies that indicate a negative 
association of depression with adherence to hormone therapy used electronic monitoring and pill 
counts to measure hormone therapy adherence only looked a prior diagnosis of depression and a 
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single measure of adherence.  No study has used a repeated measures analysis to determine the 
effect of concurrent depression on adherence to hormone therapy in breast cancer.  The literature 
suggests that a history of depression negatively effects survival; however, only one study has 
examined the effect of concurrent depression with survival and it was not in a United States 
population.  No study in the United States has examined the effect of concurrent depression on 
survival in breast cancer patients.  Depression increases cost in breast cancer; however, the 
incremental cost of depression in these patients has not been reported.  Literature that examined 
the impact of antidepressant use on adherence, survival and cost in the depressed breast cancer 
population is sparse.  The literature indicates that treating depression may improve adherence and 
survival but increase cost.  The effect of antidepressant use on direct medical cost in the 
depressed population is unknown.  There are three questions from this literature review: 1) is 
adherence to hormone therapy improved in the depressed population that uses antidepressants? 2) 
is survival improved in the depressed population that uses antidepressants? 3) what is the impact 
of antidepressant use in those with a diagnosis of depression on cost? 
 
2.6 Specific Aims and Hypotheses  
 
This study has three aims: 
1) To explore the association of depression and antidepressant use with hormone therapy 
adherence in hormone receptor positive breast cancer patients 
H1A: Breast cancer patients with depression will have lower adherence to 
hormone therapy then those without depression. 
H1B: Breast cancer patients with depression and taking antidepressants will have 
improved adherence to hormone therapy then those with depression not taking 
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antidepressants 
2) To explore the association of depression and antidepressant use with survival in hormone 
receptor positive breast cancer patients  
H2A: Breast cancer patients with depression will have a shorter survival time 
compared to those without depression 
H2B: Breast cancer patients with depression and taking antidepressant will have 
increased survival compared to those with depression and not taking 
antidepressants   
3) To explore the association of depression and antidepressant use on direct medical cost in 
hormone receptor positive breast cancer  population 
H3A: Breast cancer patients with depression will have increased cost compared 
to those without depression 
H3B: Breast cancer patients with depression and taking antidepressants will have 





Table 2.1: Studies Examining the Association of Depression and Adherence to Hormone Therapy 
Author 
(year) 











Adherence 89 Depression has a non- 
significant increase in 
adherence in tamoxifen group 
and non- significant decrease 








and persistence  
288 A CES-D score of 23+ 
associated with non -
significant decrease in risk of 










within 3 years  
12,412 Depression associated with a 











6,626 Depression associated with a 
significant decrease in the risk 






Adherence  110 Depression not significantly 




COMBO study Discontinuation 
and duration of 
therapy 
538 Depression or mood changed 
associated with non- 
significant increase in the 






Adherence  91 A higher Beck score at 
baseline associated with 




linked data from 





of  therapy 
1,531 Pre-existing depression 
associated with non -
significant increase in the risk 
of discontinuing therapy in 
unadjusted and adjusted 
models 
        
New depression associated 
with significant increase in 
the risk of discontinuing 
therapy in unadjusted model 
for initial therapy 
         
New depression associated 
with non- significant increase 








Relevant Results  






Adherence  1,479 A higher GDS score 
associated with a significant 













Relevant Results  
Onitilo 
(2006) 
NHANES 1 All- cause 
mortality  
10,025 Those with cancer and 
depression have a 
significantly higher risk of 
dying compared to those 
without cancer or depression 
         
In breast cancer, there is a 
non- significant increase in 
the risk of dying in the 
depressed group compared 











20,593 Depression before surgery is 
associated with an increased 
risk of death 
        Depression after surgery is 
associated with increased 
risk of death in early stage 
cancer patients but a non- 










1,646 Those with depression have 
a slightly significant 
increase in the risk of all -
cause mortality and a non- 
significant increase in breast 
cancer specific mortality 
 
       Depression is significantly 
associated with an increased 
risk of mortality in early 
stage patients  
Goodwin 
(2004) 
SEER 3 year hazard of 
death 
19,645 Depression significantly 















Relevant Results  
Bambauer 
(2007) 
MCBS Cost related 
non-
adherence  
13,835 Those with cancer and depression 




MEPS Total health 
care 
expenditures  
4,766 Cancer patients with depression have 
higher unadjusted expenditures  
        Cancer patients with depression have 
significantly higher total and 
prescription cost after adjusting for 






medical cost  
50,147 Men with depression during 
treatment of prostate cancer have 
significantly higher cost all around  
         
Men with depression during or after 
treatment of prostate cancer have 






Total cost to 
DoD 
11,014 Cancer patients with depression had 
lower unadjusted total cost but 






Total cost to 
DoD 
2,851 Breast cancer patients with 
depression have twice the unadjusted 













Relevant Results  
Navari 
(2007) 
Clinical trial Completion 
of treatment 
at 6 months  
193 Mildly depressed breast cancer 
patients on the antidepressant 
fluoxetine showed significantly 
higher 6 month completion of any 








161 Tamoxifen patients on 
antidepressants had a non- 










4,715 Those on antidepressants showed a 
significant reduction in adherence to 

















drugs and cancer 





24,430 Paroxetine showed 
significantly increased hazard 
of death from breast cancer 
and all causes  
        Other antidepressants showed 
a non- significant increase or 
decrease in hazard of death 





cancer registry  
Cancer 
related death 
857 Using a CYP2D6 inhibitor 
(antidepressant etc.) is 
associated with a non- 








129 Those with depressive 
symptoms and taking 
fluoxetine show a non- 
significant decrease in survival 
compared to placebo 
Goodwin 
(2001) 
RCT in Canada Survival  235 Breast cancer patients in group 
therapy show no difference in 
survival  
         
Group therapy did reduce 





Survival  227 Breast cancer patients in group 
therapy show no difference in 
survival  
         
Group therapy did reduce 




RCT in California  All- cause 
mortality  
101 An increasing depressive score 
(CES-D) is associated with an 
increased risk of death 
         
A decreasing depressive score 














Relevant Results  
Strong 
(2008) 
UK RCT Health care 
cost 
200 Average direct cost of 
intervention was $523 
     
Intervention 
cost  
   
Those in group therapy for 










125 Intervention of therapy had a 
non- significant higher cost  
        If patient distressed at baseline 
then therapy had a non -
significant lower cost  
Simpson 
(2001) 
RCT in Canada  Billed cost  89 No difference between therapy 
and control for mean billed cost 
         
Therapy group had significantly 
lower billed cost for those in the 
upper quartile of billed cost  
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CHAPTER 3 METHODS 
3.1 Introduction 
 
This chapter will describe the methods used to determine the final sample, define the 
main independent and dependent variables, and covariates and describe the type of analyses used 
for this study.  Details on the data source, sample selection, variable operationalization, 
confounders and analysis are covered in this chapter.  This is a retrospective cohort design and an 
explanation of this design and its application to this study will be discussed in this chapter. 
3.2 Data source  
 
The merged SEER-Medicare data set was used for this study.  SEER-Medicare is a 
comprehensive data set that is comprised of the SEER cancer registry and Medicare Claims. 
The Surveillance Epidemiology and End Results program (SEER) is a comprehensive cancer 
registry for the United States that started in 1973.  SEER collects detailed information on incident 
cancer cases, which includes primary tumor site, stage, first course of treatment and vital status.  
SEER also routinely collects detailed demographic information for these incident cancer cases.  
SEER currently covers ~30% of the United States population in all geographic region and the 
data is used in calculating population rates (survival, incidence etc) for the United States101. 
Medicare is a federal health insurance program for those who are 65 and older or those 
with end stage renal disease or other disabilities.  Medicare claims include Part A, Part B and Part 
D claims.  Medicare patients have the option of enrolling in Parts A and B (government 
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insurance) or in Part C (HMO, private insurance).  Part A claims consist of inpatient hospital 
claims and Part B claims consist of outpatient hospital claims and physician visit claims.  Parts 
and B have claims information starting in 1991.  Part A and B claim information includes cost of 
the claim to Medicare, procedure performed, diagnosis for procedure and the date of the claim.  
Part D is prescription drug coverage that contains drug claims since July 2006.  Part D claim 
information includes the date of dispensing the drug, generic and brand name of the drug, and the 
days supplied.   
SEER data was merged with Medicare claims using last name and social security number 
by CMS and the final data de-identified.  The merged dataset is considered representative of the 
United States population.  The final dataset contained unique patient identifiers to link between 
SEER data and Medicare claims101.  The data was provided in four files: SEER, Part A, Part B 
and Part D.  SEER-Medicare data for 2005-2010 was used for this study.   
3.3 Study Design  
 
This is a retrospective cohort design.  Patient information was collected one year prior to 
and up to four years after breast cancer diagnosis.  This design is used because this study uses 
previously collected information and follows a past cohort of breast cancer patients (2006-2009), 
from a specific point in time, date of diagnosis, forward to the most current time available102.   
Based off previous studies, the conceptual framework uses identified socio-demographic 
and clinical factors that are related to depression in breast cancer patients.  These factors are 
income, stage at diagnosis, treatment (radiation, chemotherapy, type of surgery), comorbidities, 
marital status, age, race and type of hormone therapy used103, 104.  In order to determine the 
association of depression, these factors are adjusted for in the analysis. 
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3.3.1 Sample Flow Chart 
The following chart represents the populations of this study to answer the main hypotheses. 
 
Figure 3.1: Sample Selection Framework 
The groups with asterisks beside them are the populations of interest for this study.  The 
primary study population has three asterisks beside it.   The populations with two asterisks were 
used to test the hypotheses that depression reduces adherence to hormone therapy, and survival 
and increases cost.  The populations with one asterisk were used to test the hypotheses that those 
with depression and taking antidepressants have decreased cost and improved survival and 












3.4 Sample selection 
 
3.4.1 Initial breast cancer population 
The breast cancer population was identified from the SEER registry using the provided 
cancer site code for breast cancer (46) for those diagnosed from 2006-2009.  Estrogen and 
progesterone receptor status was determined from the registry using provided indicator variables 
for these biomarkers.  Those with known estrogen or progesterone receptor positive status were 
included in the final sample.  Of these patients, those with non- metastatic breast cancer and who 
were at least 65 at diagnosis were kept for analysis.  Metastatic status was determined using the 
7th edition of the AJCC breast cancer staging system of those with stage IV were considered 
metastatic105.  Age was determined by a provided recode variable that indicated an age group at 
diagnosis.  The included age groups were 65-69,70-74, 75-79, 80-84 and 85+.  Of these patients, 
only those on hormone therapy were included.   
3.4.2 Hormone therapy use 
Hormone therapy was determined by a SERM or AI claim in Medicare Part D within a 
year of cancer diagnosis.  SERMS and AIs were identified using the brand name of the drug.  For 
example, a claim of arimidex for patients taking anastrozole.  A frequency of brand names was 
done and matched with hormone therapy agents presented by breastcancer.org and the Susan G 
Komen website.  Patients with hormone receptor positive breast cancer starting hormone therapy 
within a year were followed in Medicare for a minimum of 1 year and up to 4 years.  Hormone 
therapy was classified as SERM only or aromatase only.  Those who had claims for both were 
excluded.   
3.4.3 Final sample for analysis 
The final sample included only those who were continuously enrolled in part A and part 
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B from 1 year prior to cancer diagnosis through  year post cancer diagnosis.  The sample was 
restricted to those who were not enrolled in an HMO at all during this time- period as HMO’s are 
private insurers, and those enrolled in an HMO will not have available information during this 
time.  This requirement was to determine co-morbidities 1 year prior to the cancer diagnosis and 
to determine depression up to a year post diagnosis.  Women with a diagnosis for schizophrenia, 
295.xx, or bipolar disorders,(296.xx) excluding 296.2 and 296.3, or those with any antipsychotic 
medication claim during the year before cancer diagnosis were excluded from the study.  Those 
with unknown stage or grade were also excluded from the final sample. 
3.5 Primary independent variables 
 
3.5.1 Depression 
Patients with ICD-9 codes 311, 296.2, 296.3, and 300.4 from a hospital or physician 
claim were classified as being depressed.  To be included in the depressed population, a patient 
had at least one claim within a year after cancer diagnosis.  Depression was classified as either 
yes or no.  Those with a depression claim within a year before cancer diagnosis were considered 
to have a history of depression.  
3.5.2 Antidepressant Use 
Antidepressant use was identified using drug name in part D claims.  Antidepressants 
were classified as a selective serotonin reuptake inhibitor (SSRI), SNRI, TCA or miscellaneous.  
Depressed breast cancer patients on antidepressants had to have at least one antidepressant claim 
after their depression diagnosis to be included in the analyses to determine the effect of 
antidepressant use on cost, survival and adherence to hormone therapy.   
To distinguish between those who used antidepressants consistently or not, a variable 
indicating the number of 30-day supply fills for an antidepressant was included.  Those with more 
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than a 30-day supply were counted in intervals of 30 based of their supply.  For example, a person 
with a 60-day supply would have a count of two for that claim.   
Continuous antidepressant use was categorized as those who continuously used an 
antidepressant for less than 90, 90, 180 or 365+ days. 
 
3.6 Primary Dependent Variables 
 
3.6.1 Adherence to hormone therapy 
Hormone therapy adherence rate was determined using the percent days covered (PDC) 
for the duration of medication use by a breast cancer patient22.  Adherence was measured for up 
to 4 years of therapy.  Adherence was measured on a quarter (90 days) by quarter basis until not 
continuously enrolled in part D or end of study.   Using this method, PDC = (days covered)/ 
(duration of medication use).  The duration of medication use is calculated from the start of 
hormone therapy to the end of the indicated quarter.  This is equivalent to 90 multiplied by the 
quarter number.  For example, the duration of medication use for the third quarter is 270, 90*3.  
The quarter number increases each quarter, so the sixth quarter represents one and half years on 
hormone therapy. In each interval, those classified as adherent had a PDC≥ 80% in order to be 
consistent with published literature on hormone therapy adherence22, 36, 51.  Adherence was 
measured while the patient was continuously enrolled in part D and was stopped if the patient was 
no longer enrolled in part D.  This restriction was applied to ensure complete information was 
available to measure adherence to hormone therapy.  If a person was not enrolled in Part D, a 





A breast cancer patient with a gap of 90 or more days between the end of their last supply 
and their next fill date for hormone therapy was classified as non-persistent19, 33, 90.  This time 
frame was chosen to be consistent with published literature. 
3.6.3 Cost 
Total direct medical cost was calculated as the sum of pharmacy, physician and hospital 
cost for provided services per patient per year from cancer diagnosis.   Cost was from the payer’s 
perspective (Medicare’s), and was the amount paid for services or drugs by Medicare.  Cost was 
inflation adjusted to 2010 U.S. dollars using the Consumer Price Index inflation calculator106.  
The analysis used accounts for the skewed nature of cost and further details are in the analysis 
section.     
3.6.4 Survival 
Survival was determined from the cancer registry and was measured in months from 
cancer diagnosis until death or December 31, 2012, which is the last day the registry has 
information on these patients.  This is a longer follow up time as the registry reports this 
information instead of using available claims for cost and adherence to hormone therapy.   
3.7 Additional covariates  
 
Patient co-morbidity was measured using the Charlson co-morbidity score a year before 
their breast cancer diagnosis.  ICD-9 codes were used to determine patients’ co-morbidity score 
with a higher score indicating more severe co-morbidities107.  Co-morbidity scores were classified 
as 0, 1 or 2+23.  Age, race, geographic location and median income of zip code were used to 
account for socio-demographic status for a person.  Age at the time of breast cancer diagnosis 
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was categorized as 65-69, 70-74, 75-79, 80-84 and 85+.  Race was categorized as white, black or 
other108.  Geographic location was determined by two variables.  The first indicated urban setting 
or not.  The second indicated SEER location, classified as northeast, north central, west and north 
central as defined by SEER109.  The median income of the zip code was classified as under $30K, 
between $30K and $50K, and over $50K previously defined in work done with SEER-
Medicare11.  Those with unknown income were not included.  Cancer stage and grade were also 
included to account for cancer severity.  Cancer stage and grade were categorical variables.   
 3.8 Analysis 
 
Descriptive statistics were used to illustrate sample characteristics and differences 
between those with depression and those without depression.  These statistics were also used to 
characterize antidepressant users and non- users in the depressed population.  Chi-square statistics 
were used to compare categorical variables across groups and the two-sample t-test was used to 
compare continuous variables across groups.  For all regression models, an a priori selection of 
variables based off the conceptual framework were used.  To test the hypothesis that those with 
antidepressant use will have improved adherence to hormone therapy in the depressed population, 
a generalized linear regression with logit-link and binomial distribution for repeated measures 
was used.  This analysis is similar to logistic regression and does yield odds ratios from the 
parameter estimates.  A generalized linear regression with log-link and gamma distribution for 
repeated measures of total cost was used to test the hypothesis that those on antidepressants will 
incur lower cost in the depressed population and to determine the incremental cost of depression.  
Kaplan Meier estimates were used to determine the initial association of depression and 
antidepressant use in the depressed population with persistence and survival.  Kaplan-Meier 
estimates and a time interaction variable in the cox proportional hazards model were used to test 
the proportional hazards assumption.  If proportional hazards were indicated (curves did not cross 
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and the interaction variable was not statistically significant), the association of depression and 
antidepressant use in the depressed population was reported from the adjusted Cox proportional 
hazards model.  If proportional hazards were not indicated, (curves did cross and the time 
interaction variable was statistically significant), the distribution was determined using a linear 
survival model that fits different distributions.  The distribution with the best fit (lowest AIC 
value) was used to estimate the association of depression and antidepressant use in the depressed 
population, adjusting for clinical and demographic characteristics.           
The following model is the general form used for the analysis for the association of 
depression with adherence to hormone therapy.  Y indicates the probability of adhering to 
hormone therapy so e^β is the adjusted odds ratio for the parameter110, 111.  For this study, e^ β1 is 
the estimate of interest as it indicates the odds of adhering to hormone therapy if a person has 
depression adjusting for demographic and clinical characteristics110. 
Log (Y/1-Y) =  β1 *depression + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6 
*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of 
depression + β12 *count indicating repeated measures 
 
The following model is the general form used for the analysis for the association of 
depression with survival. Hi represents an individual’s hazard of death and t indicates length of 
time a person survives.  H0 is the baseline hazard function.  No assumption is needed for the 
baseline hazard function when there are proportional hazards between groups and H0 is not in the 
model.  If proportional hazards are not indicated, then H0 is in the model as a baseline hazard 
function for the sample.  For this study, e^(β1) is the estimate of interest as it indicates the risk of 
death if a person has depression adjusting for demographic and clinical characteristics112. 
Hi(t) =  H0 * (e^(β1 *depression + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6 
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*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of 
depression) ) 
The following model is the general form used for the analysis for the association of 
depression with cost.  Y represents total cost per patient per year and Log (E(Y|variable)) is the 
log cost based off the log link used for this association.  For this study, β1 is the estimate of 
interest as it indicates the increase in cost a person has depression adjusting for demographic and 
clinical characteristics113.  The intercept in this case is baseline cost for the sample and estimates 
are added to the intercept for the total cost94.   
Log (E(Y|variable)) = intercept+ β1 *depression + β2 * age + β3 *race + β4 *co-morbidity + β5 
*SEER site + β6 *urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade 
+ β11 *history of depression + β12 *count indicating repeated measures 
 
 
The following model is the general form used for the analysis for the association of 
antidepressants with adherence to hormone therapy in the depressed population.  Y indicates the 
probability of adhering to hormone therapy so e^β is the adjusted odds ratio for the parameter110, 
111.  For this study, e^ (β1 is the estimate of interest as it indicates the odds of adhering to hormone 
therapy if a person has depression adjusting for demographic and clinical characteristics. 
 Log(Y/1-Y) =  β1 *antidepressants + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6 
*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of 




The following model is the general form used for the analysis to determine the 
association of antidepressants with survival in the depressed population.  Hi represents an 
individual’s hazard of death and t indicates length of time a person survives.  H0 is the baseline 
hazard function.  No assumption is needed for the baseline hazard function when there are 
proportional hazards between groups and H0 is not in the model.  If proportional hazards are not 
indicated, then H0 is in the model as a baseline hazard function for the sample.  For this study, 
e^(β1) is the estimate of interest as it indicates the risk of death if a person with depression uses 
antidepressant adjusting for demographic and clinical characteristics112.   
  Hi = H0 * e^( β1 *antidepressants + β2 * age + β3 *race + β4 *co-morbidity + β5 *SEER site + β6 
*urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer grade + β11 *history of 
depression + β12 * number of 30 day antidepressant supplies)  
The following model is the general form used for the analysis to determine the 
association of antidepressants with cost in the depressed population.  Y represents cost and Log 
(E(Y|variable)) is the log cost based off the log link used for this association.  For this study, β1 is 
the estimate of interest as it indicates the increase in cost a person with depression uses 
antidepressants adjusting for demographic and clinical characteristics113.  The intercept in this 
case is baseline cost for the sample and estimates are added to the intercept for the total cost94.   
  Log (E(Y|variable)) = intercept+ β1 *antidepressants + β2 * age + β3 *race + β4 *co-morbidity + 
β5 *SEER site + β6 *urban + β7 *cancer stage + β8 *chemotherapy + β9 *radiation+ β10 *cancer 
grade + β11 *history of depression + β12 * number of 30 day antidepressant supplies + + β13 * 
count indicating repeated measures 
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CHAPTER 4 RESULTS 
4.1 Overview   
 
This chapter begins with a description of breast cancer patients with and without a 
diagnosis of depression followed by a description of those breast cancer patients with depression 
who use antidepressants and those who do not.  Results related to hypotheses H1A-H3B will 
follow and addressed separately.  For each hypothesis, the association of depression is estimated 
followed by the test of the hypothesis.  A concluding statement indicates if the results support the 
indicated hypothesis.  Results are presented in the following order: 1) the association of 
depression and antidepressant use with adherence to hormone therapy 2) the association of 
depression and antidepressant use with survival and 3) the association of depression and 
antidepressant use with cost in breast cancer patients.   
The hypotheses to be tested are: 
H1A: Breast cancer patients with depression will have lower adherence to 
hormone therapy then those without depression. 
H1B: Breast cancer patients with depression and taking antidepressants will have 
improved adherence to hormone therapy then those with depression not taking 
antidepressants 
H2A: Breast cancer patients with depression will have a shorter survival time 
compared to those without depression
51 
H2B: Breast cancer patients with depression and taking antidepressant will have 
increased survival compared to those with depression and not taking 
antidepressants   
H3A: Breast cancer patients with depression will have increased cost compared 
to those without depression 
H3B: Breast cancer patients with depression and taking antidepressants will have 
reduced direct medical cost compared to those with depression and not taking 
antidepressants 
 
4.2 Baseline Characteristics  
 
The SEER registry included 147,081 women with breast cancer satisfying the preliminary 
inclusion criteria.  The majority (72%) had a diagnosis of  hormone receptor positive cancer.  
After restricting the population to those 65 and older, not diagnosed at autopsy, not enrolled in an 
HMO and took hormone therapy within a year of cancer diagnosis, 10,471 were further identified 
as depressed (N=1,073) or not depressed (N=9,398) (figure 4.1).  The enrollment and metastatic 
restriction is where the most patients were lost in the final selection for the sample population 
(figure 4.1).   Of the 10,471 hormone receptor positive breast cancer patients taking hormone 
therapy, 8,522 (81%) took an AI and 1,949 (19%) took a SERM.  The depressed population made 
up 10% of the final study sample, which is consistent with the 7% found in Goodwin's study in 
the general SEER-Medicare breast cancer population54. The depressed population differed 
significant from the non-depressed population on several factors.  These include a history of 
depression, more co-morbidities, and more severe cancer (table 4.1).  Consistent with more 
advanced cancer is the choice of a mastectomy, an invasive procedure, compared to breast 
conserving surgery.  Consistent with Goodwin, those who are not married and white are more 
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prevalent in the depressed population.  Those with radiation treatment are significantly fewer in 
the depressed population (table 4.1).  
Of the 1,073 depressed patients, 664 (62%) had an antidepressant claim after their diagnosis of 
depression.  For antidepressant users, 339 (51%) took an SSRI, 94 (14%) took an SNRI. 56 (8%) 
took a TCA and 175 (26%) took a different antidepressant.  Those taking antidepressants had 
more history of depression, lower grade cancers, and were younger (table 4.2).  No other 
significant differences were observed between antidepressant users and non-users. 
 
4.3 Adherence to Hormone Therapy 
 
4.3.1 Association of Depression with Adherence to Hormone Therapy 
For reference, this section is testing hypothesis H1A: Breast cancer patients with 
depression will have lower adherence to hormone therapy then those without depression.   
Consistent with previous studies, the number of patients who stayed adherent to hormone 
therapy reduced over time (figure 4.2).  Table A.1 presents the number of patients observed in 
each quarter.  Fewer patients (statistically significant) adhered to hormone therapy in the 
depressed group compared to the non-depressed group (figure 4.2).  Depressed patients had 
significantly lower PDC values compared to the non-depressed group (table 4.3).  Of note, the 
difference in mean PDC values between the depressed and non-depressed group consistently 
increased over the length of time a patient was on hormone therapy.  In the GLM with a logit link 
and binomial distribution (test of H1A), depression was associated with a 19% reduction (p<0.01) 
in the odds of adhering to hormone therapy after adjusting for various clinical and demographic 
variables (table 4.4).  Those with a history of depression had a 15% reduction (p<0.01) in the 
odds of adhering to hormone therapy.  The repeated measures variable indicating the number of 
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measures a person had was associated with a 9% reduction (p<0.0001) in the odds of adhering to 
hormone therapy.  Other factors that were significantly associated with reduced odds of adhering 
to hormone therapy were AI use, in a Midwest or South SEER site, and age>74 and in an urban 
area.  Factors that were significantly associated with increased odds of adhering to hormone 
therapy were a mastectomy and a race that was neither black nor white. 
Adherence to hormone therapy does reduce over time, which is shown in unadjusted 
counts and mean PDC values for each quarter and in the adjusted GLM model.  Those with 
depression consistently have reduced adherence to hormone therapy over time, which is reflected 
in both unadjusted count and mean PDC values for each quarter.  The unadjusted values and the 
adjusted value from the GLM model provide support for hypothesis H1A that patients with 
depression do have reduced adherence compared to those who do not have depression. 
4.3.2 Association of Antidepressants with Adherence to Hormone Therapy  
For reference, the hypothesis tested in this section is H1B: Breast cancer patients with 
depression and taking antidepressants will have improved adherence to hormone therapy then 
those with depression not taking antidepressants 
The sample size for the test of hypothesis H1B is in table A.2 and reflects the number of 
patients analyzed in each quarter.  In breast cancer patients with depression (depressed sample), 
antidepressant users had higher PDC values compared to non-users, but the difference was not 
statistically significant (table 4.5). 
There was little difference in the percent of patients who were adherent to hormone 
therapy between antidepressant users vs non-users for quarters 1-7.  Antidepressant users were 
consistently more adherent to hormone therapy compared to non-users starting at quarter 8 in the 
depressed sample (figure 4.3).  Antidepressant users had a significantly higher percentage of 
patients who adhered to hormone therapy (55%) compared to non-users (45%).  These results 
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indicate that antidepressant use is associated with improved adherence to hormone therapy in the 
depressed sample; however, this difference varies across the period of treatment.   
To determine the association of antidepressant use with adherence to hormone therapy 
(test of H1B), a GLM was used for repeated measures to adjust for confounders.  After adjusting 
for clinical and demographic characteristics, antidepressant use was associated with a non- 
significant 21% decrease in the odds of adhering to hormone therapy.  The indicated negative 
association potentially reflects the severity of depression, as those with more severe depression 
are more likely to be on antidepressants.  Figure 4.3 suggests that duration of antidepressant use is 
an important factor to consider as a benefit was shown only after 8 quarters of hormone therapy 
adherence measures.  To account for the benefit of extended antidepressant use, patients were 
classified by the length of time they continually used antidepressants (<90 days, 90-179 days, 
180-364 days, 365+ days).  In the GLM model, antidepressant users who continually took an 
antidepressant for a year had a 340% increase in the odds of adhering to hormone therapy 
(p<0.0001) compared to non-users (table 4.6).  This marked increase in the probability of 
adherence to hormone therapy indicates that those who are depressed and use antidepressants 
benefit from long- term use of antidepressants.     
Those on antidepressants have improved adherence over time in the depressed sample; 
however, this benefit is seen for continual use of antidepressants over time.  The results do not 
fully support the stated hypothesis that breast cancer patients with depression and taking 
antidepressants have better adherence compared to those not taking antidepressants.   
4.3.3 Persistence to Hormone Therapy 
Those with depression consistently had a significantly shorter time in persisting with 
hormone therapy (median 23 months), compared to those without depression (median 27 months) 
(figure 4.4).  The proportional hazards assumption was met and the adjusted association of 
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depression with persistence to hormone therapy was assessed with the Cox proportional hazards 
model.   Those with depression had a non-significant 106% increase in the risk of non-persistence 
to hormone therapy adjusting for clinical and demographic characteristics.  Those with a history 
of depression had a 115% increase (p<0.05) in the risk of non-persistence to hormone therapy.  
Other factors significantly associated with non-persistence to hormone therapy are charlson score 
(2+), stage (2+), grade (3+), from a western SEER site, and age (85+).  A mastectomy is the only 
factor that is associated with a significantly reduced risk of non-persistence (7% reduction).   
Those who have a history of depression have a significant increase in non-persistence 
while those with concurrent depression have a non-significant increase in non-persistence.  As the 
majority of depressed patients also have a history of depression, this result could indicate that 
chronic depression is the reason for non-persistence rather than newly diagnosed depression.  A 
condensed variable that combines history of depression with concurrent depression to reflect this 
close association was considered; however, as the focus of this study is the association with 
depression with and without a history of depression, the condensed variable was not used.   
In the depressed population, those on antidepressants had increased time persisting with 
hormone therapy (median 24 months) than those who did not take an antidepressant (median 21 
months) (figure 4.5).  Those who continually used antidepressants had increased persistence from 
90 days of antidepressant use (median 24 months) to 1 year of antidepressant use (median 32 
month) (figures 4.6-4.8).  General antidepressant use was associated a non-significant 104% 
increase in the risk of non-persistence to hormone therapy (table 4.8).  Surprisingly, those who 
used antidepressants continuously for 180 days had a significant 131% increase in the risk of non-
persistence.  This could be due to side effects, inability to handle multiple medications over a 
period of time or other reasons that are not able to be determined at this time.  Those who 
continually used antidepressants for a year showed a significant 45% reduction in the risk of non-
persistence to hormone therapy.  This indicates that the length of time on antidepressants is 
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critical for depressed patients to benefit from this therapy.  Other factors significantly associated 
with non-persistence are stage (3+), chemotherapy use and age (85+).  No other factors were 
significantly associated with persistence.     
Persistence and adherence are connected, as those who are not persistent are not adherent.  
The persistence to hormone therapy results reflect adherence to hormone therapy results: 
depression reduces adherence to hormone therapy and persistence to hormone therapy, and 
antidepressant use for a year improves adherence to hormone therapy and persistence to hormone 
therapy in patients with depression.  These results indicate that it is continual use of 
antidepressants, not general use, which improves adherence to hormone therapy.  The overall 
results support hypothesis H1A (depression reduces adherence to hormone therapy) but do not 




4.4.1 Association of Depression with Survival 
For reference, the hypothesis tested in this section is H2A: Breast cancer patients with 
depression will have a shorter survival time compared to those without depression. 
The depressed population had lower survival compared to the non-depressed population 
(mean 57 months vs 63 months).  The longer survival time reflects SEER data reported through 
2012 for these patients instead of 2010 in the claims.  Those in the depressed group always had 
lower survival compared to the non-depressed group (figure 4.9).  The proportional hazards 
assumption was not met for this population.  In order to adjust the association of depression with 
survival for confounders, a test for the underlying distribution of the hazard function was done.  
The underlying hazard distribution for this population was determined to be lognormal after 
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testing potential distributions and choosing the best fit based off the lowest AIC value.  A 
parametric model using this underlying distribution was used to determine the adjusted 
association of depression with survival.  Those with depression had a 31% decrease in survival 
after adjusting for clinical and demographic characteristics (p<0.05) (table 4.9).  Those with a 
history of depression had a non -significant 7% decrease in survival.  This is not consistent with 
Goodwin's finding for a history of depression and survival; however, Goodwin did not look at 
concurrent depression or adjust for clinical factors.  As the majority of those with depression also 
have a history of depression, it is likely that Goodwin's result (HR= 1.42) is split between the two 
variables in this analysis and any other difference is likely attributed to further adjustment for 
clinical variables that decrease survival.   Other factors associated with a significant decrease in 
survival were Charlson score (1+), stage (1+), grade (2+), a southern SEER site, black, age (74+), 
and income (30K+).  Factors associated with a significant increase in survival time were having a 
mastectomy, radiation therapy, a race other than white or black, in an urban area and married. 
Concurrent depression significantly reduces survival in breast cancer patients and over 
time those who are depressed are less likely to survive compared to those who are not depressed.  
The results support hypothesis 2A stating depression does negatively affect survival. 
4.4.2 Association of antidepressants with Survival 
For reference, the hypothesis to be tested is H2B: Those with depression and taking 
antidepressant will have increased survival compared to those with depression and not taking 
antidepressants.   
In the depressed sample, antidepressant use had a similar mean survival time (57 months) 
compared to the non-users (56months).  General antidepressant use did not have any effect on 
survival in breast cancer patients with depression (figure 4.10).  As previously determined, the 
length of time antidepressants are used is a critical factor in determining a benefit for using them 
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in the depressed population.  Antidepressants users for at least 90 days had a mean survival time 
of 58 months and overlap with non-users, which reflects the original full antidepressant 
population (figure 4.11).  This indicates that 90 days is not enough time to gain any survival 
benefit from taking antidepressants if depressed.  Antidepressant users for under 90 days had a 
mean survival time of 32 months and a marked drop in survival time after 10 months was 
indicated in this population (figure 4.11).  These results potentially indicate that if a depressed 
person is going to use an antidepressant, they are better off not taking it than taking it for less than 
90 days.  The proportional hazards assumption was not met and further adjustment was done 
using the underlying log normal distribution.  After adjusting for confounders, 90 day 
antidepressant users had a non -significant 151% increase in survival compared to antidepressant 
users for less than 90 days.  Antidepressant non-users had a non-significant 169% increase in 
survival compared antidepressant users for under 90 days after adjusting for confounders (table 
A.5).  Antidepressant users for 180 days had a mean survival time of 60 months compared to 52 
months for antidepressant non-users.  Those who continuously used an antidepressant for 180 
days always had a better survival time.  As seen with the 90 -day users, antidepressant users for 
less than 180 days had the worst survival (figure 4.12).  Adjusted estimates were determined 
using the underlying log normal distribution.  In this model, antidepressant use for less than 180 
days had a non- significant 18% decrease in survival compared to no antidepressant use adjusting 
for confounders.  Antidepressant use for 180 days had a non-significant 13% increase in survival 
adjusting for confounders (table A.6).  Antidepressant users for at least a year had a mean 
survival time of 58 months compared to 56 months in antidepressant users under 1 year.  
Antidepressant users for a year always had better survival replicating the 90 and 180-day results.  
In this instance, non-users of antidepressants and non-continual users were similar to each other 
(figure 4.13).  Adjustment using the underlying log normal distribution model showed that those 
who did not use antidepressants had a 55% decrease (p<0.05) in survival compared to those who 
did use an antidepressant for a year.  Those who did not use an antidepressant for a year had a 
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60% reduction (p<0.05) in survival compared to those who did use an antidepressant for a year 
adjusting for confounders (table A.7).   Any benefit from using antidepressants for those with 
depression likely occurs after the first 180 days of continuous use and the benefit appears to 
increase as the length of time of use increases.     
The results do not support hypothesis H2B (survival is improved with general 




4.5.1 Unadjusted cost for those with Depression and those without Depression 
For reference, the sample size for each year of cost is found in table A.3. 
In the first year after breast cancer diagnosis, depressed patients had non-significant 
lower median cost.  In subsequent years patients with depression had higher median cost which 
was statistically significant for years 2, 3 and 5 after cancer diagnosis (table 4.10).  Over time, 
cost in both groups went down, particularly from year 1 to year 2 after cancer diagnosis.  Those 
with depression might have lower cost in the first year due to not taking prescriptions or 
following through with chemotherapy or radiation treatment.  After the first year, those with 
depression likely incur greater cost due to cancer recurrence (not taking hormone therapy or did 
not receive chemotherapy etc.) or hospitalization due to depression or other reasons.     
4.5.2 Association of Depression with all cost 
For reference, the hypothesis tested in this section is H3A: Breast cancer patients with 
depression will have increased cost compared to those without depression. 
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A depression diagnosis was associated with a non- significant increase in per patient per 
year cost after adjusting for clinical and demographic characteristics.  Those with depression 
incurred $230,960.04 (intercept + depression estimate) per patient per year cost compared to 
$208,981.29 (intercept) for those without depression adjusting for clinical and demographic 
characteristics.  The incremental cost of depression was $21,978.75 (depression cost – non-
depression cost, p>0.05) per person per year adjusting for clinical and demographic 
characteristics (table 4.11).  Surprisingly, depression did not significantly increase cost; however, 
as the model adjusted for other co-morbidities and cancer severity this is not as surprising.  Both 
cancer stage and the comorbidity score significantly increased cost.  Patients with depression do 
have more comorbidities and more severe cancers, so their cost will be higher due to these 
factors.  It is likely that patients with depression already have doctor’s visits planned and do not 
incur additional doctor’s visits because they have depression.  In this case, the comorbidity score 
and cancer stage variables capture these visits instead of the depression variable, which would 
indicate why the $21,978.25 is not significant.      
The stated results do not support hypothesis H3A that depression increases cost; 
however, the estimate was positive and indicated an increase in cost for patients who have 
depression. 
4.5.3 Unadjusted cost in the depressed population for those using antidepressants and those not 
using antidepressants 
For reference, table A.4 indicates the sample size for each year for antidepressant users 
and non-users in patients with depression. 
Those who took antidepressants had non-significant higher median cost in the depressed 
population in all years except year 2 after cancer diagnosis (table 4.12).  In year 2, those on 
antidepressants had significantly higher costs.  As depression was diagnosed within a year of 
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cancer diagnosis and antidepressant use was required to be after the depression diagnosis, the 
significant increase in cost in year 2 probably reflects the initiation of antidepressants.  As some 
antidepressants are costly, the initiation is likely the reason for significantly higher cost.  It is 
possible that antidepressant use over time decreases medical cost but the magnitude is not 
sufficient to offset the prescription cost of the antidepressant or potentially increased physician 
visits to continue using antidepressants.   
4.5.4 Association of antidepressants with all Cost 
For reference, the tested hypothesis is H3B: Breast cancer patients with depression and 
taking antidepressants will have reduced direct medical cost compared to those with depression 
and not taking antidepressants 
Antidepressant users did not have significantly increased cost after adjusting for clinical 
and demographic characteristics (table 4.13).  Antidepressant users incurred $178,082.11 per 
patient per year compared to $150,241.61 adjusting for clinical and demographic characteristics.  
The incremental cost for antidepressant use was $27,840.50.  As mentioned earlier, these patients 
are likely seeing a doctor and are not incurring significantly increased cost.  In addition to a single 
doctor’s visit covering multiple comorbidities and cancer severity, antidepressant use could also 
keep patients out of the hospital and so would potentially reduce cost due to reduced hospital 
visits.  As antidepressants are expensive, it is likely that the reduced cost from fewer hospital 
visits does not offset the increase in cost of the antidepressant.  This balance would also explain 
why the increased cost is not statistically significant.   As the benefit of antidepressant use was 
seen over time in previous results, the duration of antidepressant was taken into account in this 
analysis.  Those who continually used antidepressants for at least 90 days indicated reduced cost.  
Cost were reduced more at 180 days of antidepressant use compared to the other categories with 
an $11,551.12 (p>0.05) reduction.  This non-significant decrease is likely indicative that the cost 
of antidepressant use is greater than the benefit of reduced hospital visits or other medical 
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complications.  It is possible that depressed patients will see a greater reduction in cost for 
continual use of antidepressants from their perspective.   
 For H3B, these results do indicate a potential reduction in cost for long- term 
antidepressant use; however, this reduction was not significant.  The results indicate that H3B 
(cost is reduced with general antidepressant use) is not supported.  It is possible that a cost utility 
study in this population will show that the extra cost of antidepressant use is worth the additional 
quality adjusted life years gained from antidepressant use.   
4.6 Summary 
The presented results established that those with depression have reduced adherence to 
hormone therapy, reduced survival and increased cost.  These results also establish that treating 
the depressed population with antidepressants for at least 180 days improves adherence to 
hormone therapy and improves survival.  From Medicare’s perspective, long-term antidepressant 
might reduce cost over several years; however, it is likely that antidepressant use is a cost 




Figure 4.1 Sample Selection 
  




105,855 with hormone 
receptor positive breast 
cancer 
Dropped those who were diagnosed at autopsy, metastatic,not continuously enrolled in part A and B 1 year prior through 
1 year post diagnosis or part of an HMO in these years 
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and 65+
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Figure 4.2 Percent of Patients Adherent to Hormone Therapy Over Time in the Depressed 
and Non-Depressed Population: Percent patients who are adherent to hormone therapy by 
quarter from start of hormone therapy in the depressed and non-depressed populations.  
Chi-square analysis was used to determine significant differences between those with 
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Figure 4.3 Adherence in Antidepressant Users and Non-Users in the Depressed 
population: * indicates significant difference from chi-square analysis between users and 


































Figure 4.4 Persistence in the Depressed and Non-Depressed Population: Kaplan-Meier 








Figure 4.5 Time to Non-persistence for Antidepressant Users and Non-Users in the 
Depressed Population: Kaplan-Meier estimates for persistence in antidepressant users and 
non-users in the depressed population 
  
Antidepressant Use 




Figure 4.6: Time to Non-persistence of Hormone Therapy in the Depressed Population 
for Antidepressant users for 90+ days: Kaplan-Meier estimates for persistence in 
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Figure 4.7: Time to Non-persistence of Hormone Therapy in the Depressed Population 
for Antidepressant users for180+ days: Kaplan-Meier estimates for persistence in 
antidepressant users for at least 180 days, less than 180 days and non-users in the 
depressed population 
  
< 180 day 
Antidepressant Use 
180+ Day Antidepressant 
Use 




Figure 4.8: Time to Non-persistence of Hormone Therapy in the Depressed Population 
for Antidepressant Users for at least 1 Year: Kaplan-Meier estimates for persistence in 
antidepressant users for at least 1 year, less than 1 year and non-users in the depressed 
population 
  
No Antidepressant  
1+ Year Antidepressant Use 




Figure 4.9 Survival in the Depressed and Non-Depressed Populations: Kaplan-Meier 








Figure 4.10 Survival for Antidepressant Users and Non-Users in the Depressed 
Population: Kaplan-Meier estimates for months survived since breast cancer diagnosis in 
the depressed population for those on antidepressants or not on antidepressants. 
  





Figure 4.11 Survival in the Depressed Population for Those Who Continuously Use 
Antidepressants for 90 Days: Kaplan-Meier estimates for months survived since breast 
cancer diagnosis in antidepressant users for at least 90 days, less than 90 days and non-
users in the depressed population 
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Figure 4.12: Survival in the Depressed Population for Those Who Continuously Use 
Antidepressants for 180 days: Kaplan-Meier estimates for months survived since breast 
cancer diagnosis in antidepressant users for at least 180 days, less than 180 days and non-
users in the depressed population 
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Figure 4.13 Survival in the Depressed Population for Those Who Continuously Use 
Antidepressants for 1 Year: Kaplan-Meier estimates for months survived since breast 
cancer diagnosis in antidepressant users for at least 1 year, less than 1 year and non-users 
in the depressed population 
  
1 + Year Antidepressant Use 
< 1 Year Antidepressant Use 
No Antidepressant  
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(N= 1,073) p-value 
History of Depression* 8.62 43.71 <.0001 
Hormone therapy type 
  
0.7 
SERM only 18.7 18.17 
 AI only 81.3 81.8 
 Charlson Score * 
  
0.001 
0 58.84 53.31 
 1 7.81 9.69 
 2+ 33.35 37 
 Stage * 
  
<.0001 
0 6.39 4.57 




 3 7.84 11.37 
 Grade  
  
0.33 
1 28.15 26.47 
 2 51.29 51.35 
 3+ 20.56 22.18 




breast conserving 62.16 53.96 
 mastectomy  37.84 46.04 
 Radiation therapy* 49.8 44.36 0.0007 
Chemotherapy 19.4 20.97 0.22 
SEER site * 
  
0.002 
orth east  22.43 21.9 
 North central  12.1 13.05 
 South  25.15 29.73 




White  85.12 89.75 
 Black  6.9 4.94 
 Other  7.98 5.31 




65-74 54.01 52.38 
 75-84 36.77 36.25 
 85+ 9.21 11.37 
 Urban 87.71 87.33 0.72 






(N= 1,073) p-value 




<30K 12.92 15.75   
30-49K 45.58 47.81   
50K+ 41.5 36.44   
    Table 4.1: Those with an * indicate significant differences at p<.05 between groups.  Chi-











History of Depression* 37.9 47.29 0.003 
Hormone therapy type 
  
0.79 
SERM only 18.58 17.92 
 AI only 81.42 82.08 
 Charlson Score  
  
0.103 
0 49.39 55.72 
 1 11.25 8.73 
 2+ 39.36 35.54 
 Stage  
  
0.399 
0 5.38 4.07 
 1 46.7 50.9 
 2 35.21 34.49 
 3 12.71 10.54 
 Grade * 
  
0.007 
1 21.03 29.82 
 2 55.01 49.1 
 3+ 23.96 21.08 
 Initial surgery 
  
0.154 
breast conserving 56.72 52.26 
 mastectomy  43.28 47.74 
 Radiation therapy 43.03 45.18 0.49 
Chemotherapy 20.54 21.23 0.785 
SEER site  
  
0.23 
North east  25.18 19.88 
 North central  12.22 13.55 
 South  28.12 30.72 




White  91.2 88.86 
 Black  4.4 5.27 




65-74 51.1 53.16 
 75-84 34.47 37.35 
 85+ 14.43 9.49 
 Urban 88.26 86.75 0.468 
Married  34.23 39.16 0.105 










<30K 15.89 15.66 
 30-49K 46.21 48.8 
 50K+ 37.9 35.54 
















Table 4.2: Those with an * indicate significant differences at p<.05 between groups.  Chi-
square analysis was used to compare between antidepressant users and non-users. 
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Table 4.3: Mean PDC values for Depressed and Non-Depressed Patients by Quarter 
Quarter Depression No Depression 
*1 86.81 89.87 
*2 80.48 84.78 
*3 77.21 81.34 
*4 74.56 78.83 
*5 73.07 77.56 
*6 71.98 76.60 
*7 71.30 75.72 
*8 70.13 74.96 
*9 68.44 74.49 
*10 67.73 73.76 
*11 66.77 73.18 
*12 66.86 72.36 
*13 65.96 71.98 
*14 63.85 70.74 
*15 61.27 69.46 
 
Table 4.3: The * indicates a significant difference (p<.05) between mean PDC values for 
the depressed and non-depressed group from the students t-test. 
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Table 4.4  Adherence to Hormone Therapy in the Depressed Population  
  Odds ratio 95% CI 
Repeated Measure * 0.911 0.91-0.92 
Depression * 0.81 0.71, 0.93 
History of Depression* 0.85 0.75, 0.96 
Hormone therapy type    
SERM only    
AI only* 0.60 0.53, 0.67 
Charlson Score     
0    
1 1.01 0.87, 1.16 
2+ 0.99 0.91, 1.07 
Stage     
0    
1 1.01 0.84, 1.20 
2 1.10 0.91, 1.33 
3 0.94 0.74, 1.19 
Grade     
1    
2 1.05 0.96, 1.15 
3+ 1.04 0.93, 1.17 
Initial surgery    
breast conserving    
mastectomy * 1.15 1.04, 1.28 
Radiation therapy 1.05 0.95, 1.15 
Chemotherapy 0.91 0.82, 1.01 
SEER site     
North east     
North central*  0.72 0.63, 0.83 
South*  0.86 0.76, 0.97 
West  0.99 0.89, 1.10 
Race    
White     
Black  1.10 0.92, 1.30 
Other * 1.50 1.28, 1.77 
Age    
65-74    
75-84* 0.87 0.80, 0.94 
85+* 0.85 0.74, 0.99 
Urban 0.85 0.74, 0.98 
Married  1.06 0.98, 1.15 
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  Odds ratio 95% CI 
Median Income of Zip 
Code 
   <30K 
   30-49K 1.01 0.88, 1.15 
50K+ 0.91 0.79, 1.05 
 
Table4.4: Those with an * indicate significant results at p<.05.  Blank cells indicate 




Table 4.5 Mean PDC Values for Antidepressant Users and Non-Users in the Depressed 
Population 
Quarter Antidepressant No antidepressant 
1 86.74 86.93 
2 80.89 79.81 
3 77.76 76.31 
4 75.50 72.99 
5 73.77 71.85 
6 71.93 72.09 
7 71.68 70.59 
8 71.03 68.41 
9 69.55 66.40 
10 68.54 66.21 
11 67.78 64.89 
12 67.97 64.84 
13 67.60 62.89 
14 64.38 62.93 
15 61.35 61.14 
 
Table 4.5: Differences in the mean PDC value for antidepressant users and non-users in 
the depressed population were tested with the student's t-test.  There were no significant 
difference at p<.05. 
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Table 4.6 Adherence to Hormone Therapy for Antidepressant Users and Non-Users in the 
Depressed Population  
 
  Odds Ratio 95% CI 
Repeated Measure 0.90 0.88, 0.92 
Antidepressant 0.79 0.55, 1.13 
Antidepressant Use       
< 90 days       
90-179 days 1.21 0.73, 1.99 
180-364 days 1.08 0.70, 1.66 
365+ days* 2.42 1.61, 3.65 
History of Depression 0.94 0.74, 1.21 
Hormone therapy type      
SERM only      
AI only* 0.69 0.48, 0.99 
Charlson Score       
0      
1 0.97 0.62, 1.51 
2+ 1.05 0.81, 1.36 
Stage       
0      
1 0.75 0.42, 1.36 
2 0.82 0.44, 1.51 
3 0.71 0.34, 1.47 
Grade       
1      
2 0.89 0.74, 1.30 
3+ 1.08 0.76, 1.55 
Initial surgery      
breast conserving      
mastectomy * 1.76 1.30, 2.39 
Radiation therapy 1.12 0.83, 1.50 
Chemotherapy 0.78 0.57, 1.08 
SEER site       
North east       
North central  0.86 0.56, 1.31 
South*  0.64 0.45, 0.93 
West  0.89 0.64, 1.24 
Race      
White       
Black  0.83 0.47, 1.46 
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  Odds Ratio 95% CI 
Other  1.42 0.83, 2.44 
Age      
65-74      
75-84 0.84 0.64, 1.09 
85+ 0.86 0.55, 1.33 
Urban 0.80 0.52, 1.22 
Married  0.93 0.71, 1.21 
Median Income of Zip 
Code       
<30K       
30-49K 1.05 0.73, 1.50 
50K+ 0.86 0.57, 1.29 
 




Table 4.7 Risk of Non-Persistence in the Depressed Population 
  Hazard Ratio 95% CI 
Depression  1.06 0.98, 1.14 
History of Depression* 1.28 1.19, 1.37 
Hormone therapy type     
SERM only     
AI only 0.98 0.93, 1.04 
Charlson Score      
0   
  1 1.07 0.98, 1.16 
2+* 1.13 1.08, 1.18 
Stage      
0     
1* 1.14 1.04, 1.25 
2* 1.17 1.06, 1.29 
3* 1.40 1.24, 1.59 
Grade      
1     
2 1.04 0.98, 1.09 
3+* 1.08 1.01, 1.15 
Initial surgery     
breast conserving     
mastectomy * 0.93 0.88, 0.98 
Radiation therapy 0.97 0.91,1.02 
Chemotherapy* 1.17 1.10, 1.25 
SEER site      
North east      
North central  1.08 0.99, 1.18 
South  1.07 1.00, 1.15 
West * 1.10 1.04, 1.17 
Race     
White      
Black  1.01 0.92, 1.10 
Other  0.96 0.88, 1.04 
Age     
65-74     
75-84 1.00 0.96, 1.05 
85+* 1.24  1.14, 1.34 
   
Urban 0.97 0.90, 1.04 
Married  0.97 0.92, 1.01 
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  Hazard Ratio 95% CI 
Median Income of Zip Code   
  <30K   
  30-49K 0.99 0.92, 1.07 
50K+ 1.03 0.95, 1.11 
 




Table 4.8 Risk of Non-Persistence for Antidepressant Users in the Depressed Population 
 
  Hazard Ratio 95% CI 
Antidepressant 1.04 0.85, 1.27 
Antidepressant Use    
< 90 days    
90-179 days 1.12 0.87, 1.45 
180-364 days* 1.32 1.02, 1.69 
365+ days* 0.55 0.44, 0.70 
History of Depression 1.09 0.95, 1.26 
Hormone therapy type    
SERM only    
AI only 0.86 0.71, 1.02 
Charlson Score     
0    
1 1.23 0.97, 1.56 
2+ 1.06 0.91, 1.22 
Stage     
0    
1 1.32 0.94, 1.84 
2 1.29 0.91, 1.82 
3* 1.83 1.23, 2.74 
Grade     
1    
2 1.01 0.86, 1.20 
3+ 1.04 0.85, 1.28 
Initial surgery    
breast conserving    
mastectomy  0.86 0.72, 1.02 
Radiation therapy 0.91 0.77, 1.08 
Chemotherapy* 1.42 1.18, 1.72 
SEER site     
North east     
North central  1.05 0.81, 1.35 
South  1.19 0.97, 1.47 
West  1.20 0.99, 1.46 
   
Race    
White     
Black  1.26 0.90,1.76 
Other  1.24 0.92, 1.68 
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  Hazard Ratio 95% CI 
Age    
65-74    
75-84 0.92 0.78, 1.06 
85+* 1.46 1.16, 1.83 
Urban 0.98 0.77, 1.25 
Married  .98 0.85, 1.14 
Median Income of Zip 
Code 
   <30K 
   30-49K 0.99 0.79, 1.24 
50K+ 1.00 0.78, 1.28 
 




Table 4.9 Adjusted Estimate for Survival in the Depressed Population 
 
  Estimate 95% CI 
Depression * -0.36 -0.48, -0.25 
History of Depression -0.07 -0.18, 0.04 
Hormone therapy type       
SERM only       
AI only 0.07 -0.03, 0.17 
Charlson Score        
0       
1* -0.29 -0.42, -0.16 
2+* -0.40 -0.48, -0.32 
Stage        
0       
1* -0.47 -0.68, -0.25 
2* -0.69 -0.91, -0.47 
3* -1.23 -1.47, -0.98 
Grade        
1       
2* -0.14 -0.23, -0.05 
3+* -0.27 -0.39, -0.16 
Initial surgery       
breast conserving       
mastectomy * 0.17 0.07, 0.26 
Radiation therapy* 0.42 0.33, 0.51 
Chemotherapy -0.01 -0.12, 0.09 
SEER site        
North east        
North central  0.001 -0.14, 0.14 
South  -0.07 -0.18, 0.05 
West  0.05 -0.05, 0.15 
Race       
White        
Black * -0.19 -0.33, -0.05 
Other * 0.18 0.02, 0.34 
   
Age       
65-74       
75-84* -0.51 -0.60, -0.42 
85+* -1.02 -1.14, -0.90 
91 
  Estimate 95% CI 
Urban 0.12 -.01, 0.24 
Married * 0.25 0.17, 0.34 
Median Income of Zip Code       
<30K       
30-49K 0.03 -0.09, 0.15 
50K+ 0.08 -0.06, 0.21 
 
Table 4.9: An * indicates significant results at p<.05.  Blank cells indicate referent group 
in analysis.  The natural exponent of estimates represents percent reduction or increase in 
survival. 
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Table 4.10 Unadjusted Costs for Depressed and Non-Depressed Patients  
Year From Breast Cancer 
Diagnosis  Non-Depressed  Depressed p-value 
1 (N=9,398 , N=1,073) $      830,524.43 $      771,597.74 0.34 
2 (N= 8,985 , N=970) $        33,057.19 $        60,376.09 <.0001 
3 (N=6,713 , N=664) $        22,918.75 $        38,931.67 <.0001 
4 (N= 4,151 , N=395) $        18,296.51 $        24,830.93 0.12 
5 (N= 1,979 , N=166) $          6,388.32 $        12,285.88 0.03 
 
Table 4.10: Median per patient per year cost that Medicare paid from date of breast 
cancer diagnosis is reported.  Year represents number of years since breast cancer 
diagnosis.  The first N value indicates the number of non-depressed patients and the 
second N value indicates the number of depressed patients in that year.  P-value is 
reported from Wilcoxon ranked sum test for non-parametric distributions.    
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Table 4.11 General Linear Model Estimates for Per Patient per Year Cost for Those Who 
are Depressed 
  Parameter Estimate 95% CI 
Intercept  12.25 11.74, 12.75 
Repeated Measure  -1.46 -1.41, -1.50 
Depression  0.10 -0.06, 0.26 
History of Depression -0.14 -0.285, 0.004 
Hormone therapy type    
SERM only    
AI only 0.09 -0.09, 0.27 
Charlson Score     
0 
   1* 0.25 0.03, 0.46 
2+* 0.43 0.28, 0.58 
Stage     
0 
   1 0.15 -0.09, 0.39 
2* 0.41 0.14, 0.68 
3* 0.42 0.11, 0.73 
Grade     
1    
2 -0.11 -0.30, 0.07 
3+ -0.02 -0.24, 0.20 
Initial surgery    
breast conserving    
mastectomy * 0.16 0.01, 0.31 
Radiation therapy* 0.23 0.09, 0.37 
Chemotherapy* 0.19 0.03, 0.36 
SEER site     
North east     
North central*  -0.47 -0.68, -0.25 
South*  -0.30 -0.48, -0.11 
West  -0.05 -0.21, 0.12 
Race    
White     
Black * 0.52 0.18, 0.86 
Other  0.20 -0.15, 0.55 
Age    
65-74    
75-84 -0.02 -0.17, 0.14 
85+* -0.44 -0.62, -0.26 
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  Parameter Estimate 95% CI 
Urban 0.11 -0.16, 0.38 
Married  0.01 -0.12, 0.14 
Median Income of Zip Code 
   <30K 
   30-49K* -0.42 -0.76, -0.08 
50K+* -0.45 -0.83, -0.08 
Total months in parts A and B 0.01 -0.01, 0.04 
Total months in part D* 0.08 0.05, 0.12 
 
Table 4.11: An * indicates significant results at p<.05.  Blank cells indicate referent 
group in the analysis.  The natural exponent of the estimate added to the intercept 
represents the total per patient per year cost to Medicare for that group.   
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 Table 4.12 Unadjusted Costs for Antidepressant Users and Non-Users in the Depressed 
Population 
 
Year From Breast Cancer 
Diagnosis No antidepressant  Antidepressant  p-value 
1 (N=409, N=664) $        771,597.74 $        771,996.68 0.65 
2 (N=367, N=603) $           43,211.73 $          68,598.79 0.02 
3 (N=240, N=424) $           30,458.02 $          41,576.25 0.06 
4 (N=132, N=263) $           21,750.93 $          27,190.20 0.23 
5 (N=56, N=110) $             6,176.56 $          16,207.32 0.47 
 
Table 4.12: Median per patient per year cost that Medicare paid in the depressed 
population from date of breast cancer diagnosis is reported.  Year represents number of 
years since breast cancer diagnosis.  The first N value indicates the number of patients in 
the no antidepressant group and the second N value indicates the number of patients in 
the antidepressant group for that year.  P-value is reported from Wilcoxon ranked sum 
test for non-parametric distributions.   
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Table 4.13 General Linear Model Estimate for Cost in Antidepressant Users in the 
Depressed Population 
  Parameter Estimate 95% CI 
Intercept * 11.92 10.82, 13.01 
Repeated measure * -2.07 -1.88 
Antidepressant 0.17 -0.19, 0.52 
Antidepressant Use       
< 90 days       
90-179 days -0.03 -0.40, 0.34 
180-364 days -0.08 -0.43, 0.26 
365+ days -0.05 -0.41, 0.31 
History of Depression -0.20 -0.46, 0.06 
Hormone therapy type      
SERM only      
AI only 0.12 -0.16, 0.40 
Charlson Score       
0      
1 0.42 -0.14, 0.99 
2+* 0.29 0.04, 0.53 
Stage       
0      
1 0.13 -0.47, 0.74 
2 0.39 -0.26, 1.04 
3 0.10 -0.58, 0.78 
Grade       
1      
2* 0.52 0.25, 0.79 
3+* 0.59 0.28, 0.91 
Initial surgery       
breast conserving      
mastectomy  0.15 -0.15, 0.45 
Radiation therapy 0.21 -0.04, 0.46 
Chemotherapy -0.06 -0.36, 0.24 
SEER site       
North east       
North central * -0.53 -0.91, -0.16 
South*  -0.54 -0.91, -0.17 
West  0.13 -0.27, 0.53 
Race      
White       
Black * 0.98 0.43, 1.52 
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  Parameter Estimate 95% CI 
Other  0.27 -0.38, 0.93 
Age      
65-74      
75-84* -0.32 -0.61, -0.03 
85+* -0.87 -1.26, -0.49 
Urban 0.35 -0.003, 0.706 
Married  -0.05 -0.34, 0.24 
Median Income of Zip Code       
<30K       
30-49K* -0.59 -0.93, -0.26 
50K+* -0.61 -0.97, -0.25 
Total months in parts A and B* 0.06 0.01, 0.10 
Total months in part D* 0.003 0.02, 0.13 
  
Table 4.13: An * indicates significant results at p<.05.  Blank cells indicate referent 
group in the analysis.  The natural exponent of the estimate added to the intercept 





CHAPTER 5 DISCUSSION 
5.1 Introduction 
 
The final chapter will provide a discussion of the results and insight for future research 
and broader applications.  A summary of the results for adherence to hormone therapy, survival 
and cost will begin each section.  For each outcome, a discussion of the effect of depression on 
that outcome will start followed by a discussion of the effect of antidepressant use in the 
depressed population on that outcome.   After the discussion, limitations will be discussed and 
how they affect the results.  The chapter will conclude with an overall summary and final 
conclusion. 
5.2 Adherence to Hormone Therapy 
 
5.2.1 The Association of Depression with Adherence to hormone therapy 
Depression was significantly associated with decreased adherence to hormone therapy.  A 
history of depression was also significantly associated with decreased adherence.  In the 
literature, mainly prospective studies have been done to determine the association of depression 
with adherence to hormone therapy20, 88, 92.  In these studies, the association of depressive 
symptoms was determined, not the association of clinical depression.  Two of these studies20, 88 
find a significant decrease in adherence, which the current results corroborate.  The third showed 
that non-adherers to hormone therapy had a higher prevalence of depressed mood but this was not 
significant in the multivariate model used to predict adherence92.  A retrospective hospital study 
99 
by Ziller found that depression had non-significant differential effects on adherence depending on 
the type of hormone therapy51.  Tamoxifen users had a non-significant increase in adherence
 while aromatase inhibitor users had a non-significant decrease in adherence.  The current results 
reflect the finding by Ziller as aromatase inhibitors did have a significant reduction in adherence 
compared to the tamoxifen group.  This study builds on the existing literature by confirming 
existing results in a previously unused data source with a different method of measuring 
adherence.  While previous work used self-report, pill count, electronic monitoring pill caps or 
the medication possession ratio (MPR) 20, 51, 88, 92, percent days covered (PDC) was used in this 
study.  While the MPR is generally used for estimating adherence in claims data, it can 
overestimate adherence114.  Percent days covered is a simpler formula that removes the worry of 
counting a day twice as can happen with early fills using the MPR114.  PDC has been used 
previously in measuring hormone therapy adherence in breast cancer22, 36; however, this is the 
first time it has been used in determining the association of depression with adherence to 
hormone therapy.  Using this method, depression is associated with a decrease in adherence to 
hormone therapy.  This is the first study to use repeated measures to determine the association of 
depression with adherence to hormone therapy in a large database.  As adherence to hormone 
therapy drops over time, the use of repeated measures accounts for this decrease.  This is seen 
with the significant negative value of the repeated measure variable in the model.  The repeated 
measure variable corroborates the established studies that show adherence to hormone therapy 
drops over time22, 33.  One limitation to note is that a causal relationship cannot be established in 
this study.  As depression was not identified before the start of hormone therapy, the temporal 
criteria is not met for Hill’s criteria for causation.  There is a potential causal association between 
a history of depression and reduced adherence to hormone therapy.  As it is definite that a history 
of depression is before the start hormone therapy, Hill’s temporal sequence criteria for causality 
is met; however, Hill’s other requirements to establish a causal relationship (specificity, strength 
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of association etc.) are not present in this study115.  Physicians should screen newly diagnosed 
breast cancer patients for depression and determine their depression history.  This screen would 
point to those at greater risk for not adhering to hormone therapy and needing more active follow 
up once hormone therapy is initiated.         
5.2.2 The Association of Antidepressants in the depressed population with Adherence to hormone 
therapy 
Continual antidepressant use was associated with significantly improved adherence to 
hormone therapy in the depressed sample.  Since depression decreases adherence, treating 
depression is thought to improve adherence to hormone therapy.  In the regression model, those 
with continual use of antidepressants had significantly improved adherence.  Only two studies 
observed any association of antidepressant use and adherence24, 81.  Navari  found antidepressant 
use improved adherence to hormone therapy81, and Trabulsi found that antidepressant use reduced 
adherence to hormone therapy24.  Trabulsi did not control for depression, so antidepressant use 
likely became a proxy for depression and it is unknown how antidepressant use affects adherence 
to hormone therapy in the depressed population.  Navari looked at those with depressed 
symptoms and found that antidepressant use improved adherence to hormone therapy.  The 
association of antidepressant use in the depressed population is unknown from this study because 
Navari only looked at those with depressive symptoms.  This is the first study to show any 
association of antidepressant use in the depressed population.  There is a slight negative 
association with general antidepressant use and adherence to hormone therapy.  The analysis did 
adjust for length of antidepressant use and this negative association could correlate to more severe 
depression because claims data does not capture information on depression severity.  Future work 
in this area would be to adjust for depression severity in determining the association of depression 
with adherence to hormone therapy.  This study established that any benefit of antidepressant use 
on adherence to hormone therapy is with prolonged use of antidepressants.  Physicians who 
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prescribe antidepressants to breast cancer patients with depression should make it clear to the 
patient that they need to be diligent in taking their antidepressant if they want to get any benefit 
from taking the antidepressant  regarding improving their adherence to hormone therapy.   
Diligence in taking one drug is associated with diligence in taking another drug as a patient who 
is taking one can easily take a second at the same time.  It is possible that just the act of taking an 
antidepressant and not the antidepressant itself improves adherence to hormone therapy in 
patients with depression.  Those who seek treatment for depression likely want to get better and 
be more diligent in taking hormone therapy regardless if the antidepressant actively reverses any 
chemical imbalance caused by depression47, 116, 117.  Future work will be to determine if these 
results are consistent in other data sources and if an active ingredient in antidepressants is needed 
to achieve the results found in this study.   
This is the first study to report an association between antidepressant use and adherence 
to hormone therapy in breast cancer patients with depression and provides a new field for 
research in breast cancer.          
5.3 Persistence to Hormone Therapy 
 
5.3.1 The Association of Depression with persistence to hormone therapy 
Those with depression had an increased risk of non-persistence after adjusting for clinical 
and demographic characteristics.  Those with a history of depression also had a significant 
association with non-persistence.  This result reflects three of the six published studies19, 29, 52.  
This study builds on two of the published studies by using a more stable and direct measure of 
depression compared to the previous studies29, 52.  Kemp used a questionnaire to determine 
depressed mood, which is influenced by when the person fills out the questionnaire and is not a 
measure of clinical depression.  Aiello Bowles used antidepressant use to determine depression, 
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which is not an accurate way of determining depression.  Antidepressants are generally used to 
treat depression, but they can be used for several purposes in addition to treating depression and 
the depressed sample is potentially overestimatmed71.  Huiart and Cluze look at the association of 
tamoxifen discontinuation and depressive symptoms in the French population19, 90.  This study 
builds on these studies as it is in the United States and uses a diagnosis of depression instead of 
depressed mood or antidepressant use for characterizing those with depression.  The study by 
Huiart used the same data as Cluze but found a non-significant decrease in non-persistence90.  An 
important distinction between these two studies is that Cluze looked at early vs late 
discontinuation of tamoxifen while Huiart looked at discontinuation in general.  Cluze only found 
increased non-persistence in those who had late discontinuation of tamoxifen19.  These results 
could indicate that those with depression are actually going to the doctor early on and are more 
motivated to continue therapy.  This explanation is also a potential reason for the results seen in 
the studies by Hadji and Kostev33, 91.  As the studies that show depression improves persistence 
are all in Europe, there could be a policy in place for those with depression getting better care, 
which would improve persistence.  The one study in the United States showed decreased 
persistence for those with depression, which this study supports.  Further study of differing 
policies between the United States and Europe for those with depression might yield the reason 
why the European studies indicate a positive association of depression with persistence and the 
United States studies indicate a negative association.   By definition, those who are not persistent 
are not adherent, as those who do not take their medicine for an extended period will not meet the 
80% requirement to be adherent.  Hypothesis H1A is supported by results from adherence to 
hormone therapy and persistence to hormone therapy.              
5.3.2 The Association of Antidepressants in the depressed population with persistence to hormone 
therapy 
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Those who used antidepressants continually had significantly improved persistence in the 
depressed population.  Of interest, continual use of antidepressants was significantly associated 
with increased persistence after adjusting for clinical and demographic characteristics.  General 
antidepressant use was associated with a non-significant increase in the risk of non-persistence 
when adjusting for clinical and demographic characteristics; however, as this was adjusted for 
time, it is likely that this increase in risk reflects more severe depression.  This result  supports the 
only previously reported study of antidepressant use and adherence by Cluze19, which showed 
decreased persistence for those taking antidepressants.  Building on Cluze's study, this study also 
accounts for length of time using antidepressants.  Those using antidepressants longer show 
improved persistence compared to those who do not.  A potential explanation is those who 
continue taking antidepressants have a more positive outlook on life, which could lead to them to 
be more persistent23.   
Results for the association of antidepressant use with adherence to hormone therapy and 
persistence to hormone therapy indicate that duration is a critical component in improving these 
outcomes in breast cancer patients with depression.  As hypothesis H1B does not take into 
account the duration of antidepressant use, the results do not support H1B. 
5.4 Survival 
 
5.4.1 The Association of Depression with Survival 
Depression was associated with a significant decrease in survival and a history of 
depression was also associated with a decrease in survival.  This is consistent with published 
literature54, 55, 57, 89.  The study by Hjerl  examined the association of survival with post-operative 
depression , controlling for pre-operative depression89.  As Hjerl's definition of pre and post-
operative is based on diagnosis, this study looked at a similar definition of depression and found 
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similar results.  Of the three United States based studies, two studies looked at concurrent 
depression55, 57 and one looked at a history of depression54.  Studies that observed concurrent 
depression did not adjust for a history of depression, which has a significant impact on survival54, 
89.  This is the first study to determine the association survival with depression adjusting for a 
history of depression.  The values reported in this study reflect published work both with 
concurrent and a history of depression and are the first to report both in the United States.  These 
results support hypothesis H2A that there is a negative association of depression with survival.   
5.4.2 The Association of Antidepressants in the depressed population with Survival 
Continual use of antidepressants significantly improved survival in the depressed sample 
with longer time taking antidepressants indicating improved survival.  The Kaplan-Meier curves 
indicate that those who are on antidepressants but are not using them have worse survival 
compared to those who do not use them at all.  This would indicate to physicians that if they 
prescribe breast cancer patients an antidepressant they should emphasize the importance of using 
the antidepressant.  Interestingly, at 90 days those taking antidepressants continually are similar 
to those with no drug while at 365 days those not continually taking an antidepressant are similar 
to those without an antidepressant.  As the 180-364 day curve is in between the 90-179 and the 
365+ day curves, antidepressant use for over 90 days is necessary to improve survival in the 
depressed population.  For physicians, if they prescribe antidepressants for the depressed 
population, they should prescribe for at least 180 days in order to improve survival in their 
patient.  This time period potentially explains why there was no difference between fluoxetine 
users and placebo patients in the study by Fisch.  In Fisch's study, fluoxetine was only given for 
52 days, which falls into the 90 day window showing no difference between users and non-users 
in this study70.   
105 
These results add to the existing literature of the impact of treating depression on survival.  While 
the literature indicates that decreasing depression symptoms improves survival82, it has not been 
shown that treating depression with group therapy or fluoxetine improves survival64, 70.  It should 
be noted that the published results for fluoxetine and group therapy were not in the depressed 
population.  One study found a negative association of SSRI (class of antidepressants) use on 
survival; however, this was not in the depressed population78.  Another study that looked at some 
antidepressants and other drugs that inhibit CYP2D6 found a non-significant improvement on 
survival28.  Again, this was not in the depressed population so the impact of antidepressants on 
survival in the depressed population was unknown until this study.  The marked difference 
between those with continual antidepressant use and those with non-continuous use could explain 
why worse survival is indicated in published studies; these patients were not continual users of 
antidepressants. 
As duration of antidepressant use is an important factor for improved survival, hypothesis 
H2B is not supported.     
5.5 Cost 
 
5.5.1 The Association of Depression with Cost 
Those with depression had higher median direct medical cost compared to those without 
depression.   No significant increase in cost was shown for those with depression in the model 
adjusting for clinical and demographic characteristics.  The incremental cost of depression was 
$21,978.75, not significant, per patient per year.  The non-significant increase in cost is possible 
because this study is from Medicare's perspective and is in the elderly population, who likely has 
multiple co-morbidities.  These patients would already be going to the physician's office, so one 
visit would take care of multiple co-morbidities, which would not significantly impact cost.  Also, 
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more advanced stage was associated with increased cost, indicating severity of cancer. As these 
factors are all correlated, the non -significant increase in cost for depression is explained as the 
significant increase is from more severe cancers and more co-morbidities are the cost drivers 
instead of depression.  Another reason for the non-significant increase is those with depression 
might stop taking medications or stop visiting their physician.  This would reduce cost because 
they are not utilizing these services; however, these patients are probably at a higher risk of being 
hospitalized and have increased cost at the hospital.  The magnitude of increased cost for these 
patients depends on the difference between the increased hospital cost and reduced physician visit 
and pharmacy cost.  Also, this study only calculated drug, physician visit, outpatient and inpatient 
hospital cost.  Costs for home health services were not included.  Those with depression might be 
more likely to use home health services but would not be captured in this study and could explain 
the non-significant increase in cost.     
The only published cost for depression and breast cancer indicated that those with 
depression had an average yearly cost of $15,471 compared to $8,297 for the non-depressed 
group60, 93.   The study was in breast cancer survivors from the military database and is did not 
report this as incremental cost.  The published cost is to the Department of Defense (DOD) and 
not Medicare.  There are key differences in these populations which would explain the 
differences in cost between this study and Jeffery’s.  Jeffery looked at veterans and a younger 
population compared to this study, which looked at the older population in Medicare.  Those who 
are younger are likely to be more healthy and have lower medical cost compared to those who are 
older and in Medicare.  This difference could explain the higher cost found in this study 
compared to Jeffery’s.  Also, Medicare and the DOD likely have different policies on what they 
will and will not cover for patients.  This difference in coverage could also explain why there is a 
difference in these two studies as the DOD may not cover all the services Medicare does or has a 
different reimbursement policy that would explain differences in this study and Jeffery’s. 
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Hypothesis H3A is not supported as depression did not significantly increase cost; however, the 
results do indicate an increase in cost for patients with depression.  It is possible that in a younger 
population with fewer co-morbidities, depression significantly increases cost.        
5.5.2 The Association of Antidepressants in the depressed population with Cost 
Antidepressant use did not significantly increase cost in the depressed population.  The 
incremental cost to Medicare for antidepressant use is $27,840.50 per patient per year.  This non-
significant increase in cost is consistent with literature for cost of psychosocial interventions in 
the breast cancer population83, 99, 100.  Continual antidepressant use for 90+ days was associated 
with a non-significant reduction in cost.  This indicates that these patients are probably reducing 
their cost because they are likely not having as many hospital visits but not enough to offset the 
cost of the antidepressant.  As mentioned before, these patients already incur significant medical 
cost elsewhere and the additional drug cost is not a significant increase from Medicare’s 
perspective.   These results indicate that continual use of antidepressants potentially reduces the 
cost to Medicare. 
5.6 Strengths  
 
This study has two major strengths: external and statistical validity.  This study has 
external validity (results generalizable to a broader population) due to the use of SEER-Medicare.  
SEER-Medicare is representative of the entire Medicare population and so these results are 
generalizable to the full Medicare breast cancer population with hormone receptor positive 
cancer.  The analysis used has statistical validity; a relationship is established between depression 
or antidepressant use and some of the studied outcomes.  The analysis uses a repeated measures 
design to follow patients over time, so it accounts for changes in the outcome over time.  As 
adherence and cost change over time, repeated measures allows for a more accurate 
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representation of what happens in the general population, which also improves external validity.    
Repeated measures also increase the statistical power to detect differences and allows for multiple 
observations per person, which improves statistical validity as a smaller population can be used to 
detect statistically significant differences.  Repeated measures plus the large sample size provides 
statistical power to detect significant differences between groups.  Model assumptions were 
checked and appropriate analysis was done if assumptions were violated, which strengthens the 
statistical validity of this study as the proper analysis was done for the data.   
This study is not able to establish causality, but there are strengths with the association of 
depression and survival that should be noted.  The association of depression with survival fulfills 
some of Hill’s criteria for causality but not all.  Hill’s criteria for strength, temporal order, 
biological plausibility and consistency are present as there is a marked increase in the risk of 
death for those with depression, there is a biological link of depression with survival, the 
literature consistently reports a negative association of depression with survival and depression is 
diagnosed before death.  Hill’s criteria for specificity is partially fulfilled because the analysis 
adjusts for various confounders that would impact survival, including a history of depression but 
cannot adjust for all factors that impact survival.  Other strengths of this study is the adjustment 
for a prior diagnosis of depression and observing antidepressant use, general and continual, in the 
depressed sample.  No United States study has reported the association of depression with 
adherence to hormone therapy, survival and cost adjusting for a prior diagnosis of depression.  
The literature reports a prior diagnosis of depression has a significant association with these 
outcomes.  Adjusting for a prior diagnosis and several confounders allows for a more precise 
estimate for the association of depression with these outcomes.  The association of antidepressant 
use in the depressed population has not been reported and is a strength of this study.  Studies that 
report the association of antidepressant use with these outcomes in the non-depressed population 
could reflect a depression diagnosis instead of the treatment.  The addition of a length of 
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antidepressant use adds strength to this study because it distinguishes those who are short term 
users from those with extend use.  This addition captures the benefit of antidepressant use and the 
general antidepressant variable would likely capture the severity of depression.  Hence, the 




The first limitation in this study is that depression is under reported in Medicare claims54.  
This is more evident in cancer patients, who are less likely to be diagnosed with depression due to 
the side effects of chemotherapy and radiation being similar to depression37.  This limitation 
indicates that those who are in the non-depressed group are likely similar to those in depressed 
group.  The more homogenous the groups, the less likely it is to find a difference between them.  
This limitation would likely reduce the power to detect differences between antidepressant users 
and non-users.  However, the use of repeated measures and as both groups had a sample size over 
300, this study was likely sufficiently powered to detect differences between users and non-users. 
The second limitation is using claims to measure adherence.  While previous work has 
been done using part D to measure use of hormone therapy, there are limitations to consider11.  
One important limitation is there is no guarantee that a person actually takes the medicine after 
they fill it at the pharmacy.  Those with multiple fills are likely to be taking hormone therapy as it 
is unlikely a person would continue to spend money on something they are not using.  Also, there 
is no way to determine why a person was not adherent or non-persistent.  Was it due to side 
effects or some other reason?  One reason could be a person was able to get free samples from 
their physician or a clinical trial11.  Those who receive free samples would not have claims in part 
D and could be counted as non-adherent when they actually were.  This would make it more 
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difficult to detect an association with adherence to hormone therapy, as the two groups would be 
more similar instead of different.     
A limitation in looking at antidepressant use in the depressed population is the inability to 
control for other types of depression treatment.  This limitation would potentially reduce 
differences between the two groups, and make it more difficult to detect an association of 
antidepressants with the studied outcomes in the depressed population.  As it has been shown that 
group therapy is effective in reducing depressive symptoms65, those in the non-antidepressant 
group could still benefit from reduced depressive symptoms by participating in group therapy.  
Those with depression generally had a history of depression and are likely already being treated 
with group therapy or antidepressants.  As severity of depression is unable to be measured, the 
antidepressant variable and history variable could be capturing the association of depression 
severity in addition to what they intend to capture.  As this study used a duration of antidepressant 
use variable in addition to a general use variable, the benefit of antidepressant use is likely 
captured in the use instead of the general variable and this study works with this limitation.   
5.8 Policy Implications 
 
These results indicate that time is an important factor with breast cancer patients.  
Adherence to hormone therapy reduces over time, survival reduces over time and cost reduces 
over time.  Physicians treating breast cancer patients need to be more aware of the issue of 
adherence to hormone therapy reducing over time.  As it is the long term use of hormone therapy 
that improves survival, effort should be made to focus on improving adherence to hormone 
therapy after the first year.  Incentives could be put in place for physicians to see their patients 
more often or for patients to prove they are taking hormone therapy as prescribed.  These 
incentives would hopefully lead to better adherence and improved survival in these patients.  The 
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feasibility of such an incentive program should be tested and determined if the additional cost of 
the incentive is worth the gain in survival. 
These results indicate that depression negatively affects adherence to hormone therapy, 
survival and cost.  For breast cancer patients, depression screening should be considered as a 
routine protocol to identify those with depression and start them on antidepressants in order to 
improve their chances of survival.  Physicians should be made aware that depression is an issue 
for breast cancer patients and these patients need increased guidance to stay with their hormone 
therapy treatment to improve survival.  For physicians who want to prescribe antidepressants to 
treat patients with depression, they should be made aware that patients need to be on an 
antidepressant for at least 180 days to start benefiting from this drug.  This study shows that cost 
is not significantly increased with continual use of antidepressants and over time cost may be 
reduced.  Potential incentives could be put in place for physicians who treat depression in breast 
cancer with antidepressants for making sure patients stick with their regimen for at least 180 days.    
Going forward a cost effectiveness analysis should be done to determine the feasibility of 
screening breast cancer patients for depression and then using antidepressants as a treatment.   
5.9 Conclusion 
 
This study shows for the first time the association of depression with hormone therapy 
adherence, survival and cost in breast cancer patients while controlling for a history of 
depression.   Consistent with the literature, this study shows that depression has a negative impact 
on adherence to hormone therapy, survival and cost.  For the first time, the association of 
antidepressants with hormone therapy adherence, survival and cost in the depressed breast cancer 
population was examined.  These results indicate that long term antidepressant use improves 
adherence and survival and potentially reduce cost. 
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Further study is needed to determine how robust these results are and if they are 
generalizable to entire breast cancer population and not just the Medicare breast cancer 
population. 
In conclusion, extended antidepressant use in the depressed breast cancer population 
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APPENDIX A: ADDITIONAL INFORMATION 
 
Table A.1 Sample Size for the Association of Depression with Adherence to Hormone Therapy 
Quarter Depressed Non-Depressed 
1 1,073 9,398 
2 1,036 9,211 
3 973 8,898 
4 882 8,177 
5 793 7,541 
6 716 6,915 
7 638 6,249 
8 550 5,460 
9 496 4,910 
10 429 4,336 
11 362 3,776 
12 280 3,073 
13 241 2,577 
14 195 2,089 
15 148 1,611 
Table A.1: The number of patients identified in each quarter who have a measure of adherence to 
hormone therapy for those with and without depression 
  
126 
Table A.2 Sample Size for the Association of Antidepressant Use with Adherence to Hormone 
Therapy for those with Depression 
Quarter Antidepressant Use No Antidepressant Use 
1 664 409 
2 643 393 
3 605 368 
4 549 333 
5 503 290 
6 458 258 
7 416 222 
8 361 189 
9 322 174 
10 280 149 
11 235 127 
12 180 100 
13 157 84 
14 124 71 
15 91 57 
Table A.2 Number of patients identified with depression who either took or did not take 
antidepressant for each quarter with a measure of adherence to hormone therapy 
 
 
Table A.3 Sample Size for Per Patient Per Year Cost for Depressed and Non-Depressed Patients 
  
Year Depressed Non-Depressed 
1 1,073 9,398 
2 970 8,985 
3 664 6,713 
4 395 4,151 
5 166 1,979 
Table A.3: The number of patients identified in each year who have a measure of cost for those 




Table A.4 Sample Size for Per Patient Per Year Cost for Antidepressant Users and Non-Users in 
Patients with Depression 
  
Year Antidepressant Use No Use of Antidepressant 
1 664 409 
2 603 367 
3 424 240 
4 263 132 
5 110 56 
Table A.4: The number of patients with depression identified in each year with antidepressant use 
or no use who have a measure of cost   
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Table A.5 Association of 90 Day Use of Antidepressants with Survival 
 
  Estimate  95% CI 
Antidepressant Category       
did not use for at least 90 days       
no antidepressant 0.99 -0.31 2.29 
used for at least 90 days 0.93 -0.37 2.22 
Hormone therapy type       
SERM only       
AI only 0.01 -0.27 0.29 
Charlson Score        
0       
1* -0.63 -0.95 -0.30 
2+* -0.37 -0.59 -0.15 
Stage        
0       
1* -0.78 -1.47 -0.08 
2* -1.05 -1.75 -0.35 
3* -1.36 -2.09 -0.60 
Grade        
1       
2 -0.22 -0.48 0.04 
3+ -0.21 -0.52 0.10 
Initial surgery       
breast conserving       
mastectomy * 0.30 0.05 0.54 
radiation therapy* 0.36 0.11 0.60 
chemotherapy 0.07 -0.20 0.34 
SEER site        
north east        
north central  0.09 -0.27 0.46 
south  -0.01 -0.32 0.31 
west  0.20 -0.09 0.47 
Race       
white        
black  -0.33 -0.75 0.08 
other  -0.17 -0.63 0.28 
Age       
65-74       
75-84* -0.36 -0.59 -0.13 
85+* -0.89 -1.21 -0.57 
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  Estimate  95% CI 
Urban -.01 -0.36 0.34 
Married * 0.29 0.06 0.53 
Median Income of Zip Code       
<30K       
30-49K 0.11 -0.20 0.42 
50K+ 0.23 -0.12 0.59 
 
Table A.5: An * indicates significant results at p<.05  
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Table A.6 Association of 180 Day Use of Antidepressants with Survival 
  Estimate  95% CI 
Antidepressant Category       
no antidepressant       
did not use for at least 180 days -0.21 -0.44 0.03 
used for at least 180 days 0.12 -0.14 0.38 
Hormone therapy type       
SERM only       
AI only* 0.03 -0.25 0.31 
Charlson Score        
0       
1* -0.61 -0.94 -0.29 
2+* -0.37 -0.59 -0.15 
Stage        
0       
1* -0.79 -1.48 -0.09 
2* -1.04 -1.74 -0.34 
3* -1.34 -2.09 -0.60 
Grade        
1       
2 -0.21 -0.46 0.05 
3+ -0.18 -0.49 0.13 
Initial surgery       
breast conserving       
mastectomy * 0.28 0.04 0.52 
radiation therapy* 0.35 0.10 0.60 
chemotherapy* 0.07 -0.20 0.34 
SEER site        
north east        
north central  0.13 -0.24 0.49 
south  0.04 -0.27 0.35 
west  0.19 -0.10 0.47 
Race       
white        
black * -0.34 -0.75 0.07 
other  -0.18 -0.63 0.28 
Age       
65-74       
75-84* -0.35 -0.58 -0.12 
85+* -0.88 -1.20 -0.57 
Urban -.01 -0.36 0.34 
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  Estimate  95% CI 
Married * 0.29 0.06 0.52 
Median Income of Zip Code       
<30K       
30-49K 0.13 -0.17 0.44 
50K+ 0.26 -0.09 0.61 
 
Table A.6: An * indicates significant results at p<.05  
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Table A.7 Association of 1 Year Use of Antidepressants with Survival 
  Estimate  95% CI 
Antidepressant Category       
used for at least 365 days       
did not use for at least 365 days* -0.92 -1.51 -0.33 
no antidepressant* -0.79 -1.39 -0.19 
Hormone therapy type       
SERM only       
AI only* 0.03 -0.24 0.31 
Charlson Score        
0       
1* -0.60 -0.92 -0.28 
2+* -0.34 -0.56 -0.12 
Stage        
0       
1* -0.81 -1.50 -0.12 
2* -1.06 -1.76 -0.36 
3* -1.37 -2.11 -0.63 
Grade        
1       
2 -0.21 -0.47 0.04 
3+ -0.19 -0.50 0.12 
Initial surgery       
breast conserving       
mastectomy * 0.30 0.05 0.54 
radiation therapy* 0.37 0.12 0.61 
chemotherapy* 0.07 -0.20 0.34 
SEER site        
north east        
north central  0.12 -0.26 0.47 
south  0.02 -0.28 0.33 
west  0.20 -0.08 0.48 
Race       
white        
black  -0.32 -0.73 0.09 
other  -0.15 -0.60 0.31 
Age       
65-74       
75-84* -0.35 -0.58 -0.13 
85+* -0.87 -1.19 -0.56 
Urban -.02 -.38 0.33 
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  Estimate  95% CI 
Married * 0.27 0.04 0.5 
Median Income of Zip Code       
<30K       
30-49K* 0.12 -0.18 0.43 
50K+ 0.24 -0.11 0.59 
 
Table A.7 An * indicates significant results at p<.05  
 
